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Normal platelet function is important for the body to maintain haemostasis. Under pathological 
conditions, platelet activity may be altered by elevated circulating priming factors. Primers can 
enhance platelet responses to physiological agonists such as thrombin and ADP, which leads 
to an increased risk of thrombus formation and resistance to anti-thrombotic drugs. Previous 
studies have identified several platelet primers including thrombopoietin, insulin growth factor 
1 and sCD40 ligands. There is evidence to suggest that more platelet primers may exist, 
however, the identity and underlying mechanism of novel platelet primers is still largely 
unknown. This project therefore aims to identify novel primers and the underlying mechanism 
by which they affect platelet function. Through literature research and platelet transcriptome 
expression studies, a list of potential platelet primers was generated. Using platelet 
aggregation studies, primers that increased protease-activated receptor 1 (PAR1)-mediated 
platelet responses were taken for further studies. Of these primers, sphingosine-1-phosphate 
(S1P) was identified as the novel platelet primer to be studied in more detail.  This study 
demonstrated that S1P exhibited a concentration dependent biphasic effect on platelet 
function, with low concentrations of S1P enhancing PAR1-mediated platelet responses, while 
inhibitory effects were observed at high concentrations of S1P. To demonstrate the 
mechanism of S1P biphasic effects and probe the S1P receptor subtypes expression on 
platelets, S1P receptors agonists and antagonists were tested in aggregation, flow cytometry, 
immunoblotting, TxB2 ELISA, Ca2+ mobilization assay and platelet spreading experiments. 
Current results suggest that the S1P’s priming effect was mediated via activation of 
phosphoinositide 3-kinase (PI3K) signalling pathway, resulting in increased integrin αIIbβ3 
activation and P-selectin exposure. No significant effect of S1P on platelet calcium signalling 
or thromboxane A2 synthesis was observed. This study also indirectly suggests that the 
S1PR1, S1PR4 and S1PR5 receptors are expressed on human platelets. The positive priming 
effect of S1P is mediated via activation of S1PR1 receptor, while inhibitory effects are likely to 
be mediated via S1PR4 and S1PR5 receptor activation. Furthermore, this study also 
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Chapter 1. General introduction 
1.1 Platelet physiology and function 
1.1.1 Overview of platelet and thrombotic disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Platelets, also known as thrombocytes, are small non-nucleated cells derived from 
megakaryocytes that circulating in the blood to stop vascular bleeding and maintain 
haemostasis 1 . Damage in the vessel can activate platelets result in blood clotting and 
formation of thrombus. Thrombosis is when a thrombus is formed within the vessel and cause 
blood flow to stop, which can lead to development of cardiovascular complications such as 
deep vein thrombosis, stroke or heart attack2. Cardiovascular disease is the major cause of 
death, which contribute to over 18 million of the total mortality worldwide3. Under normal 
physiological conditions, platelet function are strictly controlled and its activity is suppressed 
by circulating antithrombotic mediators 4 . However, disruptions in this strictly regulated 
process might result in elevated platelet response and lead to development of thrombotic 
disorders. Current therapeutic strategies to prevent thrombosis include use of anti-coagulants, 
thrombolysis drugs or antiplatelet agents. Besides off target effects such as gastrointestinal 
bleeding, certain population of patients also have shown resistance to antiplatelet drugs5. 
Genetic variations between individuals might contribute to antiplatelet resistance. However, 
several studies have found that the concentrations of certain bioactive molecules were 
elevated in these patients, resulting in altered platelet responses to physiological agonists 
and a higher risk of developing thrombotic disorder6. Bioactive molecules that cause platelet 
hyperactivity and resistance to antiplatelet therapy are classified as “platelet primers”. 
Previous studies have identified several platelet primers such as thrombopoietin (TPO), 
insulin growth factor 1 (IGF-1), sCD40 ligand and prostaglandin E2 (PGE2)7. Recent research 
suggests that more platelet primers exist. Hence, identifying novel platelet primers and 
determining the underlying mechanism by which they increase platelet function can provide 
us with a better understanding of pathological platelet function, which might lead to the 
development of novel therapeutic strategies to treat cardiovascular disease8.  
 
1.1.2 Platelet activation and signalling. 
Under in vivo blood flow condition, platelets are pushed towards the vessel wall due to the 
small cell size and discoid shape thus circulating along the endothelial lining9. Healthy intact 
vascular endothelium constantly releases antithrombotic factors, in particular, prostacyclin 
(PGI2), nitric oxide (NO) and anti-thrombin factors III to supress the flowing platelets activity 
and inhibit the coagulation pathway10 . Injury or disruption in the endothelial wall cause 
exposure of sub-endothelial matrix, which contain several thrombogenic components include 
collagen, von Willebrand factor (vWF), tissue factors (TF), fibronectin and laminin (Fig. 1). 
These thrombogenic factors can activate and interact with receptors expressed on the platelet 
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surface, lead to tethering and capture of circulating platelets to the sub-endothelium. The 
platelet adhesion process is initiated by the interaction between vWF in the extracellular 
matrix and glycoprotein Ib-IX-V receptor complex expressed on platelets11 (Fig. 1). Binding of 
glycoprotein VI receptors to the sub-endothelial collagen results in platelet activation and 
stimulates activation of integrin α2β1, α5β1, and αIIbβ3. These integrins are adhesion receptors 
that can interact with collagen, vWF and fibrinogen, resulting in firm and irreversible adhesion 
of platelets to the sub-endothelial matrix and formation of stable platelet-platelet aggregate12 
(Fig. 1). 
 
Figure 1. Schematic diagram illustrating the mechanism of vascular injury and subsequent 
platelet adhesion, activation and aggregation. AA: arachidonic acid; ADP: adenosine diphosphate; 
PGG2: prostaglandin G2; PGH2: prostaglandin H2; Cox-1: cyclooxygenase 1; PAF: platelet-activating 
factor receptor; PAR: Protease-activated receptor; TP: thromboxane receptor. (Figure adapted from 
Badimon et al 13) 
Activation of GPVI receptor results in inside-out signalling and activation of integrins. GPVI 
activates phospholipase C (PLC), initiate production of diacylglycerol (DAG) and IP3. 
Downstream effects of DAG and IP3 cause of Ca2+ mobilisation and activation of integrin αIIbβ3, 
the effect of integrin αIIbβ3 will be discussed in more detail later. Activated integrins can also 
signal outside-in triggering the platelet degranulation process. DAG and Ca2+ can regulate the 
activity of protein kinase C (PKC), which mediate platelet granule secretion. An increase in 
Ca2+ also activates phospholipase A2 resulting thromboxane A2 (TxA2) synthesis. 
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Synthesized TxA2 and granule released ADP can activate G-protein coupled receptors 
(GPCRs) expressed on platelets. Activation of Gα12/13 coupled GPCRs leads to downstream 
activation of the Rho family of small GTPases, which play important roles in regulating 
intracellular actin rearrangement and cytoskeletal dynamics14. Family members include RhoA, 
Rac1 and Cdc42 and these regulate platelet adhesion, shape change and granule secretion 
process via control the formation of stress fibre, lamellipodia and filopodia respectively. A 
study on Rac1 knock out mice demonstrated that Rac1 controls lamellipodia formation in 
platelets and inhibition of Rac1 significantly reduced platelet aggregate strength 15 .Upon 
activation, platelets change shape from discoid shape to a spiculated sphere with many 
filopodia protrusions formed on the surface. This platelet morphology change and the 
spreading process greatly increase the cellular surface area, which allows further platelet-
platelet interactions and aggregate formation to take place and enables subsequent granule 
exocytosis16.  
1.1.3 Platelet calcium mobilization, granule secretion and TxA2 production  
Activation of the GPVI receptor induces intracellular calcium release and the subsequent 
platelet granule secretion process. Many studies have demonstrated the importance of 
calcium signalling in platelet activation 17 . Activation of the GPVI receptor results in 
phosphorylation of the immune-receptor tyrosine-based activation motif (ITAM) on the FcRγ 
chain, which causes activation of Src family kinases Fyn and Lyn18 (Fig. 2). Fyn and Lyn 
recruit and activate spleen tyrosine kinase (Syk), phospholipase C-γ (PLCγ) and 
phosphoinositide 3-kinase (PI3K). PLCγ2 activation leads to IP3 production and subsequent 
activation of the inositol trisphosphate receptor (IP3R) on the dense tubular system (DST) 
causing calcium release. Elevated cytosolic calcium promotes subsequent platelet 
degranulation, thromboxane A2 production, GRCRs signalling and integrin αIIbβ3 activation 
(Fig. 2). The overall effect of these platelet responses is amplification of platelet activation 
and aggregation processes, resulting in the formation of stable aggregates and promoting 
thrombus growth. These platelet functional responses can easily be measured and quantified 
by experimental approaches to assess the overall platelet responsiveness.  
Platelet granule secretion is mediated by PKC and Ca2+. There are two types of granules in 
platelets, alpha granule and dense granule together contain many bioactive molecules ready 
to be released. Alpha granules contain cytokines and growth factors such as IGF-1, platelet-
derived growth factors (PDGF). Some adhesion factors including vWF, fibrinogen and 
coagulation factors are also stored in alpha granules19. Moreover, adhesion molecules such 
as P-selectin, αIIbβ3 integrin and additional GPVI receptors are present within the alpha 
granules and can be translocated to the platelet cell membrane to enhance platelet adhesion 
and activation. The surface content of P-selectin can be measured by a fluorescent labelled 
antibody and used to quantify platelet granule secretion. Dense granule is another type of 
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granule, which releases ADP that can activate the purinergic G-protein coupled P2Y12 (Gαi) 
and P2Y1 (Gαq) receptors in both autocrine and paracrine manner20  (Fig. 1). In addition, 
serotonin and histamine are released from dense granules, which contributes to stabilising 
thrombus formation and facilitates the coagulation pathway 21 . Furthermore, continuous 
granule release builds up a high local concentration of pro-coagulation factors which can 
counteract the effects brought by antithrombotic factor such as PGI2 and NO22.  
 
Figure 2. Schematic representation of platelet activation resulting in subsequent calcium 
release, GPCRs signalling and integrin activation.  ADP: adenosine diphosphate; PGI2: 
prostaglandin I2; PI3K: phosphatidylinositol-4, 5-bisphosphate 3-kinase; Akt: protein kinase B. PLC: 
phospholipase C; PKC: protein kinase C; Rap1b: Ras-related protein 1b; RIAM: Rap1-GTP-interacting 
adaptor molecule (Figure adapted from Kaushansky et al23) 
In addition to granule secretion, another important platelet agonist is thromboxane A2, which 
is synthesized by activated platelets. A rise in intracellular calcium concentration activates the 
calcium dependent phospholipase A2 (PLA2), PLA2 catalyses phospholipids on the DTS 
surface to arachidonic acid (AA), AA is converted to prostaglandin G2 (PGG2) by 
cyclooxygenases (COX) and subsequently to prostaglandin H2 (PGH2) by peroxidase24 (Fig. 
1). TxA2 is generated from PGH2 by thromboxane synthase, which can bind to the Gαq 
coupled thromboxane receptors resulting in further calcium release and promoting 
aggregation strength. TxA2 can counteract the anti-coagulate effect of prostacyclin receptors 
and also acts as a strong vasoconstrictor to enhance endothelial cell responses and 
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chemokine release25. Low dose aspirin exhibits anti-thrombotic effects by irreversibly blocking 
cyclooxygenase thereby inhibiting TxA2 synthesis. 
1.1.4 GPCRs signalling and integrin αIIbβ3 activation in platelets 
There are three major types of GPCRs involved in regulating platelet function, the P2Y family 
of GPCRs, protease activated receptors (PAR) and thromboxane receptors (TP)26. The G 
protein coupled purinergic receptors P2Y1 and P2Y12 can be activated by ADP released from 
dense granules, resulting in the recruitment and activation of surrounding platelets and the 
continuous stimulation of granule release. This positively feedback loop enhances the overall 
activation cascade and promotes platelet aggregation. Clopidogrel, Prasugrel or Ticagrelor 
are clinically used P2Y12 receptor inhibitors, which reduce platelet activity and lower the risk 
of cardiovascular events. In addition to the P2Y family GPCR, protease-activated receptors 
play important roles in regulating platelet function and the aggregation consolidation process. 
Platelet activation causes phosphatidylserine (PS) expressed on the inner cytosolic 
membrane to be flipped and externalized, which creates a catalytic surface that attracts 
proteases and coagulation factors such as Factors Va, VIIIa and XIII. As shown in Fig. 1, 
Factors Va and Factors Xa together form the prothrombinase complex which cleaves 
prothrombin to thrombin. Thrombin is a serine protease that can cleave the amino acid motif 
SFLLRN on the G-protein coupled PAR receptors, resulting in self-activation of the receptor27 
(Fig. 2). Human platelets express PAR1 and PAR4 receptors and activation of the Gαi/o, Gαq 
and Gα12/13 coupled PAR1/4 receptors results in downstream signalling such as calcium 
release, granule secretion, platelet shape change and integrin αIIbβ3 activation. Furthermore, 
PAR1 signalling also activates the mitogen-activated protein kinase (MAPK) pathway, of 
which the downstream effector extracellular signal related kinase (ERK) can contribute to 
thromboxane A2 synthesis. In contrast, activating Gαs coupled prostacyclin receptor (IP) will 
result in cAMP increase and platelet inhibition28. 
Integrin αIIbβ3 is the most abundant integrin expressed in platelets, which is a heterodimer 
complex consists of αIIb and β3 subunit (Fig. 2). Both α and β subunit have a large extracellular 
domain, a transmembrane spanning region and a cytoplasmic tail29. In resting platelets, both 
subunits are in a bent form which keeps the integrin αIIbβ3 at a “low affinity” state. Activation 
of the GPVI receptor or Gαq coupled PAR1, TP or P2Y1 receptor increases cytosolic calcium 
concentrations, resulting in activation of calcium-diacylglycerol guanine nucleotide exchange 
factor I (CalDAG-GEFI) and Rap1b. Rap1b activates talin-1 and Kindlin resulting in a 
conformational change in the β3 subunit, cause extension and exposure of the integrin head 
domain, which transforms integrin αIIbβ3 to a high-affinity state (Fig. 2). This “inside-out 
signalling” process activates integrin αIIbβ3 and allows binding of fibrinogen and vWF between 
different αIIbβ3 integrin receptors on platelets. The formation of fibrinogen bridges cross links 
neighbouring platelets resulting in the formation of a stable aggregate (Fig. 2). The final 
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platelet aggregate consolidation process is mediated by thrombin cleavage of fibrinogen 
resulting in a fibrin network 30 . As previously described, thrombin was synthesized from 
enzymatic cleavage of prothrombin by Factor Xa and Factors Va complex.  Thrombin can 
activate Factors XIII that cleave fibrinogen to produce insoluble fibrin. Fibrin polymerises and 
binds platelets to form a fibril mesh31. Activated Factors XIII also cross links the fibrils-platelets 
aggregate mesh, resulting in stabilisation of the platelet plug. Furthermore, outside-in 
signalling via αIIbβ3 integrins results in clot retraction and strengthening of the clot. Therefore, 
targeting the αIIbβ3 integrins receptors can disrupt the fibrin network formation process which 
reduces platelet aggregate formation. Abciximab, Tirofiban and Eptifibatide are integrin αIIbβ3 
receptor inhibitors used in the clinic for coronary intervention and prevention of thrombotic 
disorders32. 
1.2 Priming of platelet function 
Platelet primers are bioactive molecules that do not induce platelet response by themselves 
but increase platelet responses to physiological agonists such as thrombin and ADP 33 . 
Diseases such as chronic inflammation, diabetes and cardiovascular disease have elevated 
circulating concentrations of certain growth factors, glycoprotein hormones, and cytokines or 
promote their receptor expression levels. For example, studies have shown that CCL17, 
CCL22 and CXCL12 enhance platelet responses to ADP, while elevated plasma 
concentrations of these chemokines were found in patient with chronic inflammation or 
myocardial infarction34. IGF-1 and TPO are identified platelet primers that can cause platelet 
hyperactivity and increased levels of these primers were found in patients with thrombotic 
diseases. In addition, studies have shown that elevated IGF-1 and TPO levels contribute to 
antiplatelet resistance, with the therapeutic effects of aspirin being compromised in the 
presence of these primers7. The priming effects of these two primers are mediated via 
activation of PI3K pathway. As shown in Fig. 3, thrombin cleavage results in activation of G-
protein coupled PAR1 receptors, which then signals downstream via the PLC pathway to 
activate CalDAG-GEFI and Rap1b resulting in integrin activation. DAG also activates PKC 
causing ERK signalling. Activation of ERK and Rap1b results in the production of 
thromboxane A2 and integrin αIIbβ3 activation. Activation of PAR1 also signals through the PI3 
Kinase pathway resulting in the production of PIP3 and subsequent PKB activation. RASA3 
is a GTPase-activating protein (GAP) that counteract the effect of CalDAG-GEFI, RASA3 can 
convert Rap1b to a GDP bind state resulting in Rap1b inhibition (Fig.3). A study by Stefanini 
et al35 demonstrated that activation of PI3K result in PIP3 production and that PIP3 can recruit 
RASA3 to the plasma membrane and inhibit its activity. Inhibition of RASA3 results in elevated 
Rap1b activity and increased integrin activation. Furthermore, PIP3 can also cause ERK 
activation and subsequent thromboxane A2 synthesis in platelets. Binding of TPO to C-MPL 
receptor and IGF-1 to IGF-R result in activation of JAK2 and IRS1 respectively, which also 
activates the PI3K pathway (Fig. 3). Cross-talk between the signalling cascades is a common 
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biological phenomenon, as different receptors expressed on the cell may share the same 
signalling components.  
 
Figure 3. Schematic diagram showing the signalling mechanism of IGF-1 and TPO in priming 
PAR1-AP mediated platelet activation. JAK2: Janus kinase 2. IRS1: Insulin receptor substrate 1 
PIP2: phosphatidylinositol 4, 5-bisphosphate. PIP3: phosphatidylinositol (3, 4, 5)-trisphosphate. PDK: 
phosphoinositide-dependent kinase. PKB: protein kinase B. ERK: extracellular signal–regulated 
kinases. PLA2: phospholipase A2. PLCβ: phospholipase C β. Rap-1b: Ras-related protein. DAG: 
diacylglycerol. RASA3: Ras GTPase-activating protein 3. CalDAG-GEFI: diacylglycerol regulated 
nucleotide exchange factor. GTP: guanosine triphosphate; GDP: guanosine triphosphate. 
However, under pathological conditions, increased circulating TPO and IGF-1 levels or over 
expression of their receptors may result in amplification of the PI3K signalling. This synergises 
with physiological agonists to induce more downstream signalling causing enhanced TxA2 
production and integrin αIIbβ3 activation, resulting in platelet hyperactivity and promoting 
aggregate formation (Fig. 3). Moreover, certain platelet primers also enhance the production 
and release of platelets from megakaryocytes resulting in thrombocythemia. Priming of 
platelet function not only increases the risk of developing thrombotic complications, but also 
reduces the efficacy of antiplatelet agents making it more difficult to treat the disease as high 
dosage or chronic usage of antiplatelet drugs might increase the risk of bleeding36. A novel 
approach to treat patients with thrombotic disorders and other pathological complications 
could be to target platelet primers in combination with traditional anti-platelet therapy. 
Therefore, it has great clinical importance to identify potential platelet primers and exam the 
underlying mechanism of their actions, which might lead to development of novel anti-




1.3 Aims and Objectives 
Platelet primers can enhance platelet responses to physiological agonists resulting in platelet 
hyperactivity and increased risk of developing thrombotic disorders. Previously, research 
have identified several platelet primers, but evidence suggests there might be more bioactive 
molecules that can act as novel platelet primers. However, the identity and underlying 
mechanism by which these primers increase platelet function is still largely unknown. This 
project aims to first identify potential novel platelet primers through literature research and 
platelet transcriptome studies, then evaluate their priming effects on platelet aggregation. One 
of these identified novel platelet primers will subsequently be studied in further detail, to gain 
in depth insight into the underlying mechanism of how novel platelet primer may enhance 
platelet function. Finally, this project will evaluate the clinical significance of the primers 




Chapter 2. Materials and Methods 
2.1 Materials  
2.1.1 Agonists, antagonists and inhibitors 
Macrophage colony-stimulating factor, interleukin-17A, interleukin-34, chemokine ligand 17 
(CCL17), chemokine ligand 22 (CCL22), Platelet derived growth factor (PDGF-AA/BB) were 
purchased from PeproTech (London, UK). Sulprostone, insulin-like growth factor 1 and 
thrombopoietin were from Research and Diagnostic Systems (Oxfordshire, UK). Sphingosine-
1-phosphate, FTY720, selective S1PR1 agonist SEW2871, S1PR2 agonist CYM5520, S1PR3 
agonist CYM5541, S1PR4 agonist CYM50260 and S1PR5 agonist A971432. S1PR1 
antagonists Ex 26, W146, S1PR2 antagonist TY52156, S1PR3 antagonist JTE-013, S1PR4 
antagonist CYM50358 hydrochloride, sphingosine kinase 1 inhibitor PF543 hydrochloride, 
non-selective sphingosine kinases inhibitor N,N-Dimethylsphingosine (DMS) and non-
selective PI3K inhibitor wortmannin were all purchased from Tocris Bioscience (Bristol, UK). 
D-erythro-Dihydrosphingosine-1-phosphate (DHS1P), GSK575594A, apyrase, indomethacin, 
prostaglandin E1 were purchased from Sigma-Aldrich (Poole, UK). FTY720-Phosphate were 
purchased from Insight Biotechnology (Wembley, UK). The target, EC50 and IC50 of S1P 
related agonists and antagonists were summarised in Table 1. 
 
Table 1. Summary of S1P related agonists, antagonist and inhibitors used in this study with 
indications of their target receptors and potency. (Data were collected from IUPHAR/BPS guide 
to pharmacology37) 
2.1.2 Immunoblotting solution and antibodies 
30% acrylamide mix (37.5:1), 1.0 M Tris pH 6.8 solution and 1.5 M Tris pH 8.8 solution were 
from National Diagnostics (Nottingham, UK). Immobilon-FL PVDF Membrane (0.45-micron 
filter) were from Merck Millipore (Hertfordshire, UK). Sodium dodecyl sulphate (SDS) were 
from GE health care worldwide (Hatfield, UK). Tetramethylethylenediamine (TEMED), 10% 
SDS solution and precision plus protein pre-stained standards were from Bio-Rad 
Laboratories (Hertfordshire, UK). Dithiothreitol (DTT) were obtained from Apollo Scientific 
(Bredbury, England). Odyssey® Blocking Buffer were from LI-COR Biosciences (Cambridge, 
UK). Primary antibodies include phospho-AKt (Ser473) antibody, phospho-p44/42(Erk 1/2) 
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MAPK (Thr202/Tyr204) antibody, phospho-VASP (Ser239) antibody, phospho-Talin (Ser425) 
antibody, phospho-serine PKC substrate antibody were purchased from Cell Signalling 
Technology (Hertfordshire, UK). Alexa Fluor® 680 AffiniPure Donkey Anti-Goat IgG (H+L) 
and Alexa Fluor® 680 AffiniPure Donkey Anti-Rabbit IgG (H+L) were the secondary antibody 
used and purchased from Jackson Immunoresearch (Cambridgeshire, UK) 
2.1.3 Reagents for flow cytometry, calcium assay and spreading experiment 
FITC-PAC1 and PE-CD62P antibody were from BD Bioscience (Berkshire, UK). Phosphate 
buffered saline (PBS), Fura-2 AM cell permeant calcium indicator and ActinGreen 488 
ReadyProbes Reagent was purchased from Thermo Fisher Scientific (Loughborough, UK). 
Ethylenediaminetetraacetic acid (EDTA) and Triton X-100 were from Sigma-Aldrich (Poole, 
UK). Fatty acid free bovine serum albumin (BSA) and FluorSaver mounting medium were 
from Calbiochem (Hertfordshire, UK).  
2.1.4 Solutions and dilutions  
Trisodium citrate, acid citrate dextrose (ACD), D-glucose, ammonium persulfate (APS), 
sodium hydroxide, NuPAGE LDS Sample Buffer (4X), Tris buffered saline (TBS) and 
polysorbate 20 (Tween 20) were from Thermo Fisher Scientific (Loughborough, UK). Dimethyl 
sulfoxide (DMSO) were obtained from VWR international (Leicestershire, UK). HEPES 
Tyrode’s (10 mM HEPES, 1 mM Magnesium, 0.5 mM monosodium phosphate, 145 mM 
sodium chloride, 3 mM potassium chloride. pH 7.2), 2-butanol, ethanol, methanol was from 
Sigma-Aldrich (Poole, UK). Trisodium citrate were dissolved in Milli-Q water to 4% w/v. PAR1-
AP, D-glucose and apyrase were diluted in HEPES Tyrode’s buffer. S1P were dissolved in 
methanol. Indomethacin, wortmannin, FTY720, FTY720 phosphate, SEW 2871, CYM 5520, 
CYM 5541, CYM 50260, A971432, Ex 26, TY 52156, JTE 013, CYM 50358 hydrochloride, 
PF543 hydrochloride, N,N-Dimethylsphingosine and Fura-2 AM were prepared in DMSO. 
Sulprostone were pre-dissolved in methyl acetate. IGF-1 were made in 0.1 M HAC and 0.1% 
BSA. All peptide ligands (m-CSF, IL-17A/34, CCL17/22 and PDGF-AA/BB) were dissolved in 
0.1% BSA solution. All stock solutions were kept in -20°C freezer. Antibodies were diluted in 
Odyssey Blocking Buffer with TBST (v/v 1:1) to optimal concentrations and kept at +4°C in 
fridge.  
2.2 Methods 
2.2.1 Isolation and preparation of human platelet 
Venous blood was collected from healthy volunteers under the regulation of local ethics 
committee. Signed consent form in accordance with the Declaration of Helsinki was obtained 
from each volunteer. Blood samples were mixed with 1 in 9 volumes of 4% trisodium citrate 
solution to be anticoagulated and then acidified with 1 in 7 ratio of acid citrate dextrose. 
Anticoagulated blood sample were then centrifuged in a Heraeus Megafuge 11 Centrifuge 
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(Thermo Fisher Scientific, UK) at 1000 revolutions per minute (rpm) for 17 minutes which then 
platelet rich plasma (PRP) were obtained. PRP were collected and supplemented with 0.02 
U ∙ mL-1 apyrase and 140 nM prostaglandin E1, then centrifuged at 1700 rpm for 10 minutes. 
The upper layer of platelet poor plasma was removed and resulted platelets pellet was 
resuspended with 2 mL modified HEPES Tyrode’s (HEPES Tyrode’s buffer, 0.1% D-glucose 
and 0.02 U · mL-1 apyrase). Platelets were diluted as 1:2000 ratio in 10 mL isoton dilution 
agent, then the density of the platelets was determined by a Z1 coulter particle counter 
(Beckman Coulter, London, UK). Platelets were resuspended with modified HEPES Tyrode’s 
to a final density of 4×108 mL-1 and rest for 30 minutes in a 30°C water bath before 
experimentations. Platelets used in FACS, calcium mobilization and immunoblotting 
experiments were isolated and rested in the presence of 10 μM indomethacin and 0.02 U · mL-
1 apyrase instead. 
2.2.2 Platelet aggregation 
Rested platelets (4×108 mL-1) were diluted to 2×108 mL-1 using modified HEPES Tyrode’s 
buffer, a volume of 250 μL of platelets were added into transparent aggregation cuvettes each 
contain a Teflon coated mini magnetic stir bar. Platelet were pre-incubated with vehicle or 
primers for 5 minutes in prior to the addition of PAR1-AP at indicated concentration. Platelet 
aggregation was performed on a Chrono-log model 490 aggregometer (Labmedics, 
Oxfordshire, UK) under 1200 rpm stirring speed with a constant temperature of 37°C. Light 
transmission changes were measured and recorded as aggregation traces. Platelets samples 
were used within 3 hours after the resting and all wastes were decontaminated by adding 
disinfectants overnight.  
2.2.3 Protein extraction, SDS-PAGE electrophoresis and immunoblotting  
Rested human platelets (4×108 mL-1) were pre-incubated with primers for 5 minutes. 
Subsequently, PAR1-AP were added into the platelet to react for 5 minutes. Platelets sample 
were lysed by adding 4X LDS NuPAGE sample buffer (62.5 mM Tris-HCl, 10% glycerol, 1% 
LDS and 0.005% bromophenol blue) supplemented with 50 mM dithiothreitol. Samples were 
kept at - 20°C before use. Platelets protein extract was completed by heating the platelet 
lysate samples at 75°C for 5 minutes. 4 μL pre-stained protein and 25 μL platelets protein 
extract were loaded separately onto a 5% Bis-Tris polyacrylamide stacking gel shaped with 
15 wells. Subsequently, the protein electrophoresis was carried out on 8% Bis-Tris 
polyacrylamide resolving gels at 100 volts constant for 90 minutes based in SDS-PAGE 
running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS). Proteins were transferred to a PDVF 
membrane using Transfer buffer (25 mM Tris, 192 mM glycine, 10% methanol) at 100 V for 
60 minutes. Subsequently, the PVDF membrane with protein transferred was blocked using 
Odyssey® blocking buffer in TBS-T (volume ratio 1:1, 50 mM Tris, 150 mM NaCl, 0.1% Tween-
20) for 1 hour. The PDVF membranes were incubated with primary antibodies (1:500 dilution) 
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overnight at + 4°C. Membranes were then washed with TBS-T for 3 times with a 5 minutes 
interval. The membrane was then incubated with the secondary antibodies (1:5000) for an 
hour at room temperature. Subsequently, the membranes were washed extensively for 5 
times with TBS-T and scanned by an Odyssey® CLx Imaging System (LI-COR Biosciences, 
UK). 
2.2.4 Fluorescence-activated cell sorting flow cytometry 
Rested platelets were diluted to 2×107 mL-1 in a modified HEPES Tyrode’s buffer, platelet was 
incubated with vehicle control or primers for 10 minutes. A master mix of FITC-PAC1 and PE-
CD62P antibody (v/v, 2:1) were loaded into a 96 well plate and mixed with vehicle control or 
increasing concentrations of PAR1-AP. Platelets pre-treated with primers were loaded into 
each well and incubated for 10 minutes to allow platelet activation and binding of antibodies. 
Platelet sample were fixed by adding 2% paraformaldehyde and read on a BD Accuri™ C6 
Plus flow cytometer (BD Bioscience). Total of 10000 events were collected from each well.  
2.2.5 Calcium mobilization assay 
Plate rich plasm was isolated as described previously, then Fura-2 AM calcium indicator was 
added to the PRP (1:1000 dilution, working concentration 4 µM) allow 60 minutes incubation 
at 30 °C. Subsequently, platelets were isolated and resuspended to 4×108/mL final 
concentration as describe before. Washed human platelets were resting for 30 minutes in 
dark at 30 °C to allow complete de-esterification of intracellular acetoxymethyl esters. 
Platelets were diluted to 2×108 mL-1 in a modified HEPES Tyrode’s buffer supplemented with 
2 mM calcium, then incubated with vehicle or primers for 5 minutes at 37 °C. Subsequently, 
platelets samples were loaded into a 96 wells plate and read on a Tecan Infinite M200 
multimode plate reader (Männedorf, Switzerland) allow 10 cycles to establish the baseline. 
Then PAR1-AP were added, and responses were recorded for the next 40 cycles. In the last 
10 cycles, Triton X-100, EDTA and TRIS were added into the system for calibration purpose.  
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2.2.6 Measurement of TxA2 synthesis (Competitive TxB2 ELISA) 
 
Figure 4. Thromboxane A2 synthesis in human platelet and summary of TxB2 ELISA. (A) 
Arachidonic acid (AA) is generated from phospholipid by phospholipase A2, AA then get converted to 
prostaglandin G2 by cyclooxygenases then subsequently to prostaglandin H2, TxA2 is generated from 
prostaglandin H2 then shortly being metabolised to thromboxane B2. (B) Schematic diagram 
summarises the TxB2 ELISA process. Supernatant collected from lysed human platelets were added 
to the ELISA wells coated with goat capture antibody, then TxB2 conjugate with alkaline-phosphatase 
were added to the well. Any unbound TxB2 or APL conjugate was washed off and para-
Nitrophenylphosphate (pNpp) substrate was added for incubation. (Figure adapted from Abcam 
Instruction38) 
TxA2 plays an important role in platelets function and thrombus formation, however it has a 
very short half-life of 37 seconds that cannot be measured directly39 (Fig. 4A). Thromboxane 
B2 (TxB2) is the inactive product of TxA2 which has a half-life of 7 minutes, while its stable 
metabolic product 11-dehydro-TxB2 has a much longer half-life of 1 hour40. Hence, 11-
dehydro-TxB2 can be used to indirectly measure the TxA2 production in platelets. Human 
platelets (4×108/mL) were incubated with vehicle control or primer for 5 minutes in 37 °C, then 
stimulated with PAR1-AP. Reaction were stopped by adding 5 mM EDTA and 200 µM 
Indomethacin. Samples were span at 12000 g and + 4 °C for 3 minutes, subsequently the 
supernatant were removed and stored in -80°C. TxB2 ELISA kits were acquired from Enzo 
Life Sciences (Exeter, UK). A set of TxB2 standard samples were prepared to generate a 
logarithmic TxB2 standard curve. The supernatant sample was diluted 1:50 with assay buffer 
provided then loaded onto a 96 wells plate coated with goat antibody. Subsequently, TxB2 
conjugate with alkaline-phosphatase was added to each well, followed by addition of 11-
dehydro-TxB2 antibody (Fig. 4B). The plate was sealed and incubated at 500 rounds per 
minute on an orbital shaker at room temperature for 2 hours. After the incubation, the well 
contents were emptied and washed three times using a diluted wash buffer. A non-
proteinaceous chromogenic substrate para-Nitrophenylphosphate (pNpp) substrate were 
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added to each well and the plate was incubated in the dark for 45 minutes. Reaction were 
stopped by adding stop solution and the plate was read at optical density (OD) of 405 nm with 
reference correction at 570 nm on Tecan Infinite M200 multimode plate reader (Männedorf, 
Switzerland). The TxB2 concentration for each sample were calculated from the TxB2 
standard curve. 
2.2.7 Human platelet spreading 
A 96 wells glass-bottom plate were coated by 100 μg/mL BSA (control) or 100 μg/mL 
fibrinogen for 1 hour, subsequently the uncoated area of the well was blocked by 3% BSA for 
30 minutes. Platelets were diluted to 7×107 mL-1 in modified HEPES Tyrode’s buffer 
supplemented with 2 mM calcium, then incubated with vehicle control or primers for 10 
minutes. Treated platelets were incubated in the wells for 60 minutes at 37°C to allow cell 
spread and adhere onto the fibrinogen coated surface. Subsequently, platelets were fixed by 
adding 4% paraformaldehyde and washed using phosphate buffered saline. Platelets were 
permeabilised for fluorescent stain entry by addition of 0.1% Triton X-100, then washed by 
PBS and incubated with ActinGreen 488 reagent for 30 minutes. Each well was washed by 
PBS buffer before loading with Fluro-keeper mounting medium solution and covered by a 5-
millimetre glass coverslip. The plate was set in a dark overnight and images were captured 
using Leica DMI6000 B fluorescent microscope (Leica Camera AG, Germany). 
2.2.8 Statistics and software  
Platelet aggregation data were recorded on Chrono-log Aggrolink software (Chronolog 
Corporation, Pennsylvania, USA). Calcium mobilization and TxB2 ELISA data were collected 
from an I-control™ microplate reader software. Platelet spreading images were analysed 
using Leica application suite X and ImageJ. Immunoblotting data were analysed by 
ImageStudio™ Lite 5.2 (LI-COR Biosciences, UK). Data were collected from at least 3 
independent observations and plotted on Histograms graphs with mean ± SEM arrow bars 
using GraphPad Prism 7.0 software (GraphPad Software, California, USA). Statistical test 
used to analyse aggregation data was Student paired t-test, assume data points were 
normally distributed. Two-way ANOVA with Bonferroni post hoc multiple comparisons were 
used to analyse FACS, Calcium mobilization and TxA2 ELISA data points on the curves. EC50 
value of the curves were compared using Student paired t-test. One-way ANOVA with 
Dunnett's test were used to analyse immunoblotting and platelet spreading data compare to 
the vehicle value. Statistical significances were indicated with asterisks on the graphs. NS, 




Chapter 3. Identification and pre-selection of novel platelet primers  
3.1 Introduction  
3.1.1 Overview of platelet primers 
Elevated platelet activity was found in patients with coronary artery disease and these patients 
also show resistance to current antiplatelet treatment. It is well established that increased 
circulating primers contribute to platelet hyperactivity41. There are several platelet primers 
have previously been identified, including IGF-1, growth arrest-specific 6 (Gas6), matrix 
metalloproteinase-1 (MMP-1), sCD40L, TPO, stromal cell-derived factor 1 (SDF-1), vascular 
endothelial growth factor (VEGF), adrenaline, histamine and serotonin42. These primers can 
be released from activated endothelial cells and platelets, or naturally be present in the 
circulating plasma. Hence, the priming effects can be mediated via both autocrine and 
paracrine manner, resulting in positive feedback of platelet responses and promotion of 
thrombus growth. Most of the known existing primers are cytokines, chemokines, hormones 
or neurotransmitters, the in vitro effects of these primers include increased platelet 
aggregation or integrin activation to physiological agonists such as ADP, thrombin and 
collagen-related peptide (CRP). Moreover, primers such as IGF-1 and VEGF also play 
important roles in regulating vascular integrity, modulating immune response and promoting 
cell growth 43 . In addition, primers also exhibit pathological roles in diabetes, chronic 
inflammations and cancer development. It is likely that there is a whole array of platelet 
primers contributing to enhanced platelet function in disease states and this project therefore 
aims to identify novel platelet primers and their underlying mechanism of action.   
3.1.2 Using human platelet transcriptome to identify potential primers 
To identify potential novel platelet primers, we focussed on candidates that meet the following 
criteria. Firstly, corresponding receptors should be expressed on platelets according to 
proteomic/transcriptomic/western blotting data, and activation of the receptors by candidate 
molecules should not inhibit platelet function. Secondly, candidate primers and/or expression 
level of corresponding receptors are elevated under pathological conditions. Thirdly, the 
concentration of candidate primer used to evoke priming effects should ideally be in a 
physiological or pathological relevant range. In addition, there should ideally be literature to 
suggest candidate primer can alter platelet response, but it has not already been well 
characterised and therefore remains relatively “novel” in the research field. Finally, this is not 
a strict criterion, but we are also interested in any candidate platelet primer that can promote 
platelet formation from megakaryocytes which might result in thrombocythemia. Using TPO 
and IGF-1 as an example, activation of certain cytokine receptor or receptor tyrosine kinases 
(RTKs) can amplify platelet signalling via amplification of the PI3K pathway. Many identified 
primers also mediate their effects via these two types of receptor.  Hence, RTK and cytokine 
receptors can be potential targets to study. Moreover, ligands that activate GPCRs on 
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platelets might be interesting to study. As previous described, activation of GPCRs such as 
PAR receptors or thromboxane receptor can directly trigger platelet response, while activation 
of Gαi/o coupled P2Y12 receptor or Gαq coupled P2Y1 receptor can amplify platelet 
aggregation44.  Studies also demonstrated activation of Gα12/13 coupled receptor can result in 
cytoskeleton changes in platelets45. In contrast, activation of Gαs coupled prostacyclin receptor 
by PGI2 will inhibit platelet aggregation, while knock out of prostacyclin receptor result in an 
increased risk of atherosclerosis46. Activation of Gαs coupled GPCR elevates intracellular 
cyclic AMP levels resulting in platelet inhibition, therefore, any ligands activating Gαs GPCR 
will be excluded from this study.  
Prior to selecting potential platelet primers, it is important to determine whether their 
corresponding receptors expressed or not. Although platelets have lost their nuclear DNA 
genome, they still retain cytoplasmic mRNA to synthesize protein47. Using transcriptomics 
technologies, we can exam the total number of RNA transcripts (or transcriptome) for every 
protein in human platelet. The transcriptome level can be used to indicate the relative 
expression level of certain proteins or receptors 48 . Work done by Rowley et al49  have 
characterized both mouse and human platelet transcriptome using next generation RNA 
sequencing techniques. The transcriptome level of GPCRs and RTKs in human platelets were 
summarised and ranked in Fig. 5. For instance, PAR1 receptor and P2Y12 receptor have the 
highest transcriptome level among all GPCRs expressed in human platelets, which measured 
a mean RPKM of 72.7 and 52.5 respectively (Fig. 5A). The chemokine receptors CCR4 and 





Figure 5. Ranked RNA transcript expression level of GPCRs and RTKs in human platelets. (A) 
Transcript expression level of GPCRs in human platelets. (B) Transcript expression RTKs in human 
platelets. RPKM: Reads Per Kilobase of transcript per Million mapped reads. Figure was generated by 
R.W.Hunter using transcriptome data from work by Rowley et al49. G-protein coupling information was 
extracted from the IUPHAR database by R.W.Hunter. 
In contrast, 5-HT2A is a serotonin receptor expressed at a low level in platelets and can 
enhance platelet aggregation. 5-HT2A receptors have a total transcriptome of 0.91 (HTR2A), 
therefore any GPCRs transcriptome below this level should raise doubts whether the receptor 
is expressed or not. The absolute minimum is the transcriptome level for complement 
component 3a receptor 1 (C3aR1, RPKM=0.0867), which is detectable in human platelets. In 
contrast, the platelet RTK expression levels are much lower in general, therefore only 
receptors that have a RPMK above 0.5 will be considered in this study (Fig. 5B). However, 
the transcriptome level is not necessarily positively correlated to the total protein synthesized. 
As small differences between the translational features encoded in the mRNA sequence can 
lead to large differences in the total amount protein expressed50. Moreover, there might be 
false positives or negative results from the transcriptome data and it should therefore not be 
used as an absolute judgement.  
3.1.3 Potential novel platelet primers included in this study 
Based on the literature and transcriptomic data, a list of candidate platelet primers was 
generated. The normal plasma concentration in healthy human individuals, corresponding 
receptor, receptor type and the receptor transcriptome expression level of the candidate 
primers are summarised in Table 2. IGF-1 and TPO are well defined platelet primers that will 
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be used as positive controls in this study. Thymus and activation regulated chemokine (TARC, 
CCL17) and macrophage-derived chemokine (MDC, CCL22) are chemokines that 
predominately expressed in thymus. The two chemokines share a very similar structure and 
have more than 1/3 of identical amino acid sequence51. Both chemokines can activate the 
Gαi/o coupled chemokine receptor CCR4, which has a relative high transcriptome expression 
level in platelet (RPKM=4.48).  It was demonstrated these two chemokines increase platelet 
responses to ADP stimulation34. Elevated plasma concentrations of CCL17 and CCL22 are 
found in patients with asthma, dementia and chronic inflammation60. Prostaglandin E2 (PGE2) 
is a prostaglandin that released from endothelial cell and activated platelets, PGE2 can induce 
concentration dependent biphasic effects on platelet function. At low concentrations PGE2 
mainly activates the Gαi coupled prostaglandin EP3 receptor to enhance thrombin-mediated 
aggregation52. Sulprostone is the synthetic analogue of the PGE2 to be tested in this study53. 
S1P is a signalling sphingolipid that activate S1P receptors, which primarily coupled to Gαi 
and G12/13. Elevated S1P concentration have been found in obesity, cancer and renal failure 
patients, and S1P has been reported to promote whole blood aggregation and induce platelet 
activation 54 . GSK5755494A is a synthetic lysophosphatidylinositol that activates G12/13 
coupled GPR55 receptor, and is a novel cannabinoid receptor agonist reported to have blood 
pressure lowering effects55. 
Moreover, m-CSF (as known as CSF-1) and IL-34 are cytokines reported to activate CSF1R 
and cause elevated risk of coronary artery disease56. Platelet derived growth factor (PDGF) 
is released from activated platelets, however the effects of PDGF on platelets are not clear. 
As some studies suggests PDGF can inhibit platelet function57, while others found it can 
enhance58 . Increased plasma PDGF level was found in patients with hypertension and 
cardiovascular diseases76. Moreover, interleukin 17A is a cytokine that have been reported in 




Table 2. List of candidate primers included in this study, their physiological plasma 
concentration, target receptor, receptor type and transcriptome level 60-80. TARC: thymus and 
activation regulated chemokine. MDC: macrophage derived chemokine. PGE2: prostaglandin E2. S1P: 
sphingosine-1-phosphate. THC: Tetrahydrocannabinol. IL-34: interleukin-34. M-CSF: macrophage 
colony-stimulating factor. PDGF-AA/BB: platelet derived growth factor AA/BB. IL-17A: interleukin 17A; 
TPO: thrombopoietin; CCR4: C-C chemokine receptor type 4. EP3: prostaglandin EP3 receptor 
GPR55: G protein-coupled receptor 55. CSF1R: colony stimulating factor 1 receptor. C-MPL: 
thrombopoietin receptor. 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 
Candidate primers listed in Table 2 will initially be tested in platelet aggregation studies. Those 
primers that enhance platelet aggregation will be taken for further signalling and functioning 
studies. The ligand that consistently promotes platelet function throughout the experiments 
and is relatively “novel” according to the literature will be selected as the novel primer to take 
forward for further in-depth studies.  
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3.1.4 Aims  
Platelet primers can enhance platelet responses to physiological agonists resulting in platelet 
hyperactivity and evidence suggest that more primers exist. A list of potential platelet primers 
was generated through literature research and platelet transcriptome studies. However, the 
effects of these candidate primers on platelet function is unknown. The aims of this part of the 
project are therefore: 
1. Identify and evaluate the priming effects of novel platelet primers from selected ligands 
using functional platelet assays. 





3.2.1 CCL17, CCL22, sulprostone and S1P enhance PAR1-AP mediated platelet 
aggregation.  
To investigate whether candidate primers that are agonists at GPCRs can enhance platelet 
function, platelet aggregation experiments were carried out by stimulating human platelets 
with subthreshold concentrations of PAR1-AP (0.6-1.0 μM) in the presence or absence of 
candidate primers. Aggregation data indicated that CCL17, CCL22, sulprostone and S1P can 
enhance PAR1-mediated platelet aggregation (Fig. 6A-Di). In the presence of 1.0 μg/mL 
CCL17, the maximal aggregation significantly increased from 7.44 ± 1.6 % to 63.4 ± 4.1 % 
(Fig. 6Aii). CCL17 enhanced the total platelet aggregation by 216%, measured as the area 
under the curve (AUC) (Fig. 6Aiii). Similarly, another CCR4 receptor ligand CCL22 
significantly increased the maximal platelet aggregation (Fig. 6Bii). CCL22 enhanced the total 
platelet aggregation by 204%, measured by the AUC (Fig. 6Biii). The enhancing effects of 
CCL17 and CCL22 on PAR1-AP mediated aggregation can also be observed at lower 
concentrations starting at 0.2 μg/mL and saturated at 1.0 μg/mL.  In the presence of 0.1 μg/mL 
sulprostone, the maximal aggregation significantly increased from 10 ± 3.21% to 72.1 ± 3.52% 
(Fig. 6Cii) The suboptimal PAR1-AP induced aggregation was significantly increased from 
13.1 ± 2.57 % to 46.5 ± 6.29 % in the presence of 100 nM S1P (Fig. 6Dii), and a 118% 
increase in the AUC was observed (Fig. 6Diii). No significant effect on platelet aggregation 




Figure 6. The effect of GPCR agonists on PAR-mediated platelet aggregation. Washed human 
platelets (2×108/mL) were treated with vehicle or candidate primers for 5 minutes. Platelet aggregation 
was induced by a subthreshold concentration (0.6-1.0 μM) of PAR1-AP and recorded for 5 minutes. 
(A-E) (i) Representative traces of PAR1-AP-mediated platelet aggregation in the absence or presence 
of 1.0 μg/mL CCL17, 1.0 μg/mL CCL22, 0.1 μg/mL sulprostone, 100 nM S1P or 1.0 μM GSK575594A.  
(ii) Histograms of percentage maximum aggregation induced by PAR1-AP in the absence or presence 
of primer. (iii) Histograms of AUC. Data are mean ± standard error of the mean.  Statistical analysis: 




3.2.2 IGF-1, IL-34 and PDGF-AA enhance PAR1-AP mediated platelet 
aggregation.  
To investigate whether candidate primers that are agonists at RTKs can enhance platelet 
function, platelet aggregation experiments were carried out by stimulating human platelets 
with subthreshold concentrations of PAR1-AP. Aggregation data indicated that IGF-1, IL34, 
and PDGF-AA enhance platelet aggregation induced by subthreshold concentrations of 
PAR1-AP (Fig. 7Ai, Bi, Di). In the presence of 0.1 μg/mL IGF-1, the maximal aggregation 
induced by subthreshold concentrations of PAR1-AP significantly increased from 9.33 ± 6.57 % 
to 44.7 ± 8.09 % (Fig.7Aii). IGF-1 also enhanced the total platelet aggregation by 246%, 
measured as the AUC (Fig. 7Aiii). IL-34 significantly increased the maximal platelet 
aggregation from 8.40 ± 1.63 % to 38.2 ± 12.5 % (Fig. 7Bii). 1.0 μg/mL IL-34 also increased 
the AUC as shown in (Fig. 7Biii). There was no significant difference between the maximal 
aggregation induced by PAR1-AP alone or in the presence of 1 μg/mL m-CSF (Fig. 7Ci, Cii). 
In the presence of 1 μg/mL PDGF-AA, PAR1-AP induced platelet aggregation was 
significantly increased from 11 ± 3.06 % to 72 ± 7.21% (Fig.7Dii) The priming effect of PDGF-
AA could be observed at lower concentrations (0.2 μg/mL, data not shown). There was no 
significant difference between the maximal aggregation induced by PAR1-AP alone or in the 




Figure 7. The effect of RTKs agonists on PAR-mediated platelet aggregation. Washed human 
platelets (2×108/mL) were treated with vehicle or candidate primers for 5 minutes. Platelet aggregation 
were induced by subthreshold concentrations (0.6-1.0 μM) of PAR1-AP and recorded for 5 minutes. 
(A-E) (i) Representative traces of subthreshold concentrations PAR1-AP induced platelet aggregation 
in the absence or presence of 0.1 μg/mL IGF-1, 1.0 μg/mL IL-34, 1.0 μg/mL m-CSF, 1.0 μg/mL PDGF-
AA or 1.0 μg/mL PDGF-BB. (ii) Histograms graph analysis of quantified percentage maximum 
aggregation induced by PAR1-AP alone or in presence of candidate primers. (iii) Histograms graph 
analysis of AUCs induced by PAR1-AP alone or in the presence of candidate primers. Data are plotted 
as mean ± standard error of the mean.  Statistical analysis: Student’s paired t-test. NS: no statistical 




3.2.3 Confirmation of TPO priming but no effect of IL-17A observed on PAR1-
AP mediated platelet aggregation.  
To investigate whether candidate primers that target cytokine receptors can enhance platelet 
function, platelet aggregation experiments were carried out by stimulating human platelets 
with suboptimal concentrations of PAR1-AP. Aggregation data confirmed that TPO enhances 
platelet aggregation induced by subthreshold concentrations of PAR1-AP7 (Fig. 8A). In the 
presence of 0.1 μg/mL TPO, the maximal aggregation induced by subthreshold 
concentrations of PAR1-AP significantly increased from 13 ± 2.52 % to 72.7± 2.60 % (Fig.8Aii). 
TPO enhanced the total platelet aggregation by 381% as data shown in Figure 8Aiii. There 
was no significant difference between the maximal aggregation induced by PAR1-AP alone 
or in the presence of 1 μg/mL IL-17A as data shown in Fig. 8B.  
 
Figure 8. The effect cytokine receptor agonists on PAR-mediated platelet aggregation. Washed 
human platelets (2×108/mL) were treated with vehicle control or candidate primers for 5 minutes. 
Platelet aggregation were was induced by subthreshold concentrations (0.6-1.0 μM) of PAR1-AP and 
recorded for 5 minutes. (A-B) (i) Representative traces of subthreshold concentrations of PAR1-AP 
induced platelet aggregation in the absence or presence of 0.1 μg/mL TPO or 1.0 μg/mL IL-17A 
respectively. (ii) Histograms graph analysis of quantified percentage maximum aggregation induced 
by PAR1-AP alone or in presence of candidate primers. (iii) Histograms graph analysis of AUCs 
induced by PAR1-AP alone or in the presence of candidate primers. Data are plotted as mean ± 
standard error of the mean.  Statistical analysis: Student’s paired t-test. NS: no statistical significance; 




3.2.4 Primers alone do not induce platelet aggregation 
Previous work demonstrated that primers such as IGF-1 and TPO do not induce platelet 
aggregation by themselves42. To confirm that all candidate primers tested cannot induce 
platelet aggregation by themselves, candidate primers were added directly to washed human 
platelets and aggregation recorded for 5 minutes. None of the candidate primers induced 
platelet aggregation by themselves (Fig. 9). 
 
Figure 9. Candidate primers do not induce platelet aggregation. Washed human platelets 
(2×108/mL) were treated with candidate primers alone and recorded for 5 minutes. (A-D) 
Representative traces of platelet aggregation induced by CCL17, CCL22, sulprostone, S1P, 







From this part of the study several candidate primers include CCL17, CCL22, sulprostone, 
S1P, IGF-1, IL-34, PDGF-AA and TPO were found to potentiate PAR-mediated platelet 
aggregation. In contrast, no significant effect on PAR-mediated platelet aggregation was 
observed in the presence of GSK575594A, m-CSF, PDGF-BB or IL-17A. In addition, no 
platelet aggregation was observed in the presence of candidate primer alone. 
3.3.1 Confirmation that IGF-1 and TPO prime platelet aggregation  
Previously it was demonstrated that IGF-1 and TPO can potentiate platelet function34. My data 
confirmed that both IGF-1 and TPO significantly increase platelet aggregation. However, the 
vehicle response induced by subthreshold PAR1-AP and the amplitude of priming effects 
were bigger than in previous works. This might be due to platelets being isolated in the 
presence of 140 nM PGE1 and 0.02 U/mL apyrase in this study, in contrast to using 10 μM 
indomethacin and 0.02 U/mL apyrase in previous work. Future work on platelet primers may 
want to consider using PGE1 and apyrase treatment, since indomethacin will block primer-
mediated TxA2 production7.  
3.3.2 CCL17, CCL22 and S1P prime platelet function via GPCR signalling 
Aggregation data confirmed that CCL17 and CCL22 can significantly increase PAR1-AP 
induced platelet aggregation. This is in agreement with Gear et al34, who demonstrated that 
CCL17 and CCL22 can enhance low dose ADP and thrombin-mediated platelet aggregation. 
Interestingly, at the same concentration of 1.0 μg/mL, CCL17 induced slightly bigger 
increases in platelet aggregation than CCL22 did. However, CCR4 competitive binding 
assays performed by Imai et al51 suggested that CCL22 has a higher binding affinity 
(IC50=0.65 nM) for CCR4 receptor than CCL17 (IC50= 2.1 nM). The priming effects of both 
chemokines can start to be observed at lower concentration (0.2 μg/mL), while several studies 
have found 5 to 10 folds increase in plasma concentration of CCL17 and CCL22 under 
pathological condition such as asthma, atopic dermatitis and Hodgkin Lymphoma. However, 
the concentration to produce a priming effect is still thousand times higher than the 
physiological plasma concentration. In addition, my data indicated that CCL17 and CCL22 
alone did not induce aggregation of washed human platelets, which is in accordance with 
Shenkman et al81. In contrast, Sylvie et al82 suggested CCL17 or CCL22 alone can directly 
induce platelet aggregation in PRP. In the clinic, inhibiting the CCR4 receptor by monoclonal 
antibody Mogamulizumab is used to treat cutaneous T-cell lymphoma83. In line with literature 
on the effect of PGE2 and sulprostone on platelet function, aggregation data confirmed that 
sulprostone at 0.1 μg/mL concentration potentiated PAR1-AP induced platelet aggregation52. 
Sulprostone is the synthetic analogue of PGE2 which can activate the Gαi/o coupled 
prostaglandin EP3 receptor (EP3), resulting in cAMP inhibition and potentiation of platelet 
function. In comparison to PGE2, sulprostone did not induce a concentration dependent 
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biphasic effect due to its high specificity on EP3 receptors over the Gαs coupled EP2 and EP4 
receptors53. However, it is worth to noting that the concentration evoking the priming effect is 
supraphysiological, even though elevated PGE2 concentration were found in patients with 
asthma or diabetes. Sulprostone is currently used in the clinic for abortion or stopping 
postpartum hemorrhage, and it is in development with other synthetic prostaglandin 
analogues to treat gastrointestinal bleeding84. The effect of S1P on platelet function is unclear. 
It was reported S1P can directly induce platelet aggregation in PRP85. However, no similar 
effect was observed in the washed human platelet system in this project. My data suggest 
that PAR1-AP mediated platelet aggregation is enhanced in the presence of 100 nM S1P. 
Later experiments also found non-physiological concentrations of S1P inhibit platelet 
aggregation, which agrees with work done by Onuma et al85. 
3.3.3 IL-34 and PDGF-AA prime platelet function via RTK signalling 
IL-34 and m-CSF both are functional ligands of CSF1 receptor but induced different effects 
on platelet aggregation. 1.0 μg/mL IL-34 (19.1 nM, kDa of 52.6) significantly enhanced PAR1-
AP mediated aggregation, whereas no obvious effect was found with 1.0 μg/mL m-CSF (27.2 
nM, kDa of 36.8) addition. A possible explanation for this discrepancy could be the structural 
differences between IL-34 and m-CSF which affect binding to and activation of CSF1R, since 
these two ligands do not share any similarity in the amino acid sequence. A study by Chihara 
et al86 suggests that IL-34 exhibits a 9 to 13-fold higher affinity than m-CSF for binding to 
CSF1R. Moreover, it was reported that IL-34 binding can produce stronger phosphorylation 
of downstream tyrosine kinases compare to m-CSF. In addition, studies on macrophages 
suggest IL-34 can increase the production and release of certain chemokines than m-CSF, in 
particular, IL-34 can elevate the synthesis of monocyte chemoattractant protein 1 (MCP1)87. 
MCP1 can bind to CCR4, which is the same receptor that CCL17 and CCL22 bind to and 
potentially further enhance platelet aggregation. Hence, the differences between amino acid 
sequence, receptor binding affinity, downstream mediator and chemokine release might result 
in different biological effects induced by IL-34 and m-CSF on human platelets. A previous 
study demonstrated that elevated local production of m-CSF contributes to the onset of 
atherosclerosis88, m-CSF also has been shown to enhance platelet recovery in patients that 
had chemotherapy89. Although one study found increased serum concentration of IL-34 in 
patients with coronary artery disease, to my knowledge there is no study have been 
conducted to investigate the effect of IL-34 on platelet function. My data indicates therefore 
for the first time that IL-34 has a priming effect on human platelets. Future studies on the 
effect of IL-34 on platelet function should be conducted.  Research by Selheim et al57 
suggested that platelet-derived-growth factor inhibits platelet activation via blocking platelet-
derived micro-particle formation. However, my aggregation results indicated that PDGF-AA 
significantly potentiates platelet aggregation by over 400%. In contrast, PDGF-BB slightly 
increased platelet aggregation, although this did not reach significance. Studies have shown 
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that PDGF-AA only binds to the PDGF-αα receptor, while PDGF-BB primarily binds to the 
PDGF-ββ receptor, but also can activate PDGF-αα or the PDGF-αβ heterodimer receptor. 
However, the transcriptome data indicates possible PDGF-α isomer (RPKM=1.48) but not 
PDGF-β (RPKM=0.115) expression in human platelets. Moreover, there is no literature 
evidence support PDGF-αβ and ββ receptor expression in platelets Therefore, PDGF-αα 
might be the only PDGF receptor expressed in human platelets. In addition, Lin et al90 using 
receptor binding assays indicated that PDGF-AA can bind to PDGF-αα receptor with higher 
affinity (Kd = 134 nM) than PDGF-BB (Kd = 420 nM). The latter may explain the smaller effect 
of PDGF-BB on platelet function. Furthermore, transcriptome data indicates high levels of 
PDGF-AA over PDGF-BB expression (RPKM of 15.5 vs 0.136), which is in line with a study 
that showed activated platelets release PDGF-AA/AB but not PDGF-BB 91 . Hence, it is 
possible that endogenous PDGF-AA released from activated platelets is competing with 
PDGF-BB on binding PDGF-αα receptor, resulting in a reduction of the effect evoked by 
PDGF-BB. It was reported that PDGF can enhance platelet production and recovery in 
thrombocytopenia mice92, but future studies are needed to investigate the mechanisms by 
which PDGF affects platelet function. In the clinic, recombinant human PDGF-BB has been 
shown to help cure stomach ulcer and counteract the side effects induced by aspirin 
treatment93. 
3.3.4 Activation of GPR55 or the IL-17A receptor has no effect on platelet 
function 
It was found that Delta-9-Tetrahydrocannabinol (THC) enhanced platelet function by 
increasing integrin αIIbβ3 activation and P-selectin exposure levels94. Recently it was reported 
that THC can also activate the Gαq coupled GPR55 receptor causing concentration dependent 
increases in cytosolic calcium concentration95. We have tested the synthetic selective GPR55 
receptor agonist GSK575594A (EC50=158 nM) using a concentration range from 10 nM up to 
100 µM. However, no effect on PAR1-AP mediated platelet aggregation nor any effect of 
GSK575594A alone was observed, despite high GPR55 transcriptome expression levels in 
human platelets (RPKM=50.9) and expression of a functional receptor96. Similarly, activation 
of IL-17A receptor by interleukin 17A showed no effect on PAR-mediated platelet function, 
although previous studies showed that elevated IL-17A plasma concentrations correlate to 
the development of acute coronary syndrome, and IL-17A promoted ADP induced platelet 
aggregation97. Future investigations might be necessary to fully probe the effect of GPR55 
and IL-17A receptors on platelets. 
3.3.5 Identification and evaluation of the platelet primer to take for further study. 
The effect and potential underlying mechanism of the candidate primers has been discussed 
in previous paragraphs. To gain more insight into the mechanism of novel primers, one primer 
will be selected for much a focused study. PDGF-BB, m-CSF, GSK575594A and IL-17A are 
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excluded from the study since no effect was observed. IGF-1, TPO and sulprostone (or PGE2) 
have already been well characterized, thus will be used as positive control throughout the 
project. Although CCL17, CCL22, PDGF-AA and IL-34 have shown priming effects, the 
concentration used to evoke responses is far higher than physiological or even pathological 
concentrations. For instance, the concentration of CCL17 and CCL22 used to evoke a 
maximal priming effect was 1.0 μg/mL, which is equal to 125 nM CCL17 (kDa of 8) or 100 nM 
CCL22 (kDa of 10). However, the concentration used is hundred times higher than the EC50 
concentration of the CCR4 receptor (0.65 and 2.1 nM respectively). In addition, these 
concentrations are much higher than the picogram range of physiological concentration. 
Hence, any priming effect induced by supraphysiological concentrations should be viewed 
with caution, as it could potentially be a non-physiological or an off-target effect. However, we 
cannot rule out that the in vitro environment might affect cellular responses. For example, 
isolation of platelets might cause receptor loss or desensitization, thus higher concentrations 
of the ligands are required to produce similar responses. Also, it is likely in an in vivo 
environment that the concentration of multiple platelet primers could be raised and therefore 
a combination of primers at lower concentrations are needed to detect a functional effect42. 
However, another problem of studying these primers is the lack of pharmacological tools such 
as receptor antagonists. Furthermore, the downstream signalling pathway and the ligand 
binding affinity remain ambiguous, whereas the cost and instability of these protein peptide 
could limit the type and number of experiments being carried out. Aggregation data suggest 
S1P can enhance platelet aggregation in a physiological relevant concentration. In contrast 
to the chemokine or growth factor family primers, there are many commercially available 
pharmacological tools with reasonable price to be used to study S1P receptors. In addition, 
the G protein coupled S1P receptors downstream signalling pathway have been well 
established in other cell lines. Furthermore, there are only a few studies have been carried 
out to exam S1P effects on platelet function and the effect on platelet function is controversial.  
Hence, S1P was selected as the “novel platelet primer” to be carried forward for further study 




Chapter 4. Investigation of sphingosine-1-phosphate mediated 
platelet priming 
4.1 Introduction 
4.1.1 Overview of sphingosine-1-phosphate 
S1P is a bioactive signalling sphingolipid that was discovered in 1993. Early research 
suggested that S1P was a product released from thrombin-stimulated platelets. However, 
later studies discovered that mast cells, red blood cells and endothelial cells also contribute 
to the production of circulating S1P98. Recent research demonstrated that S1P released from 
red blood cells and endothelial cells is responsible for maintaining plasma S1P concentration, 
while activated platelets contribute to build up of local S1P concentration and facilitated the 
blood clotting process on injured endothelium (Fig. 10). Circulating S1P is associated with 
albumin or high-density lipoprotein (HDL), which limits the bioavailable S1P concentration in 
tissue fluid resulting in a physiological S1P gradient. Early studies recognised S1P as a 
cellular secondary messenger98, however, later studies found that S1P can activate the G 
protein coupled lysophospholipid family S1P receptors. S1P is an important mediator in 
regulating vascular integrity and permeability, also play a role in immune system to control 
immune cells migration99. 
 
Figure 10. Schematic diagram showing the synthesis, transportation, degradation and 
signalling process of sphingosine-1-phosphate. RBC: red blood cells; ApoM: apolipoprotein M; 
ApoA-I: Apolipoprotein A-I; HDL: High-density lipoprotein; SMase: sphingomyelinases; CERase: 
ceramidases; SPHK: sphingosine kinase; SPP: sphingosine-1-phosphate phosphatase; SPL: 
sphingosine-1-phosphate lyse; ABC transporter: ATP-binding cassette transporter. Figure adapted 
from Rivera et al99. 
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4.1.2 Sphingosine-1-phosphate synthesis and degradation 
S1P synthesis is a stimulation dependent event100. Shear stress or activation of RTKs, 
cytokine receptors and GPCRs can result in activation of sphingomyelinases, ceramidases 
and sphingosine kinase (Fig. 10). The sphingomyelin in the cell membrane lipid bilayer is 
broken down by activated sphingomyelinases to ceramide, which in turn is deacylated by 
ceramidases to form sphingosine. Sphingosine then gets phosphorylated by the sphingosine 
kinase to generate sphingosine-1-phosphate. Synthesized S1P can be transported out of the 
cell via ABC transporters, then bind to apolipoprotein M rich HDL or albumin and entering the 
circulatory system100. The intracellular and circulating S1P concentration is tightly regulated 
by two enzymes: sphingosine-1-phosphate phosphatase (SPP) and sphingosine-1-
phosphate lyase (SPL). SPP can dephosphorylate S1P to sphingosine, which in turn is 
resynthesized to ceramide by ceramide synthase, subsequently sphingomyelin synthase 
covert the ceramide to sphingomyelin (Fig. 10). Alternatively, S1P can be irreversibly broken 
down by SPL to form hexadecimal (hex) and phosphoethanolamine (PE) for the synthesis of 
other phospholipids98. The expression level of SPP and SPL are inversely related to the local 
concentration of S1P. For instance, the average S1P concentration in tissue is about 100 nM 
due to high SPL expression level, in contrast, the serum S1P concentration is much higher at 
about 0.5 to 1.4 μM101. Studies also indicated that RBC and endothelial cells can store S1P 
and contribute to the high circulating S1P concentration, due to SPL not being expressed in 
RBC, and both the SPL and SPP expression are suppressed in endothelial cell102. Platelets 
lack of both SPP and SPL and the concentration of S1P in platelets is about 0.1 nM per 4x108 
cells, however, platelets only contribute to local S1P concentration upon activation. 
Furthermore, the S1P concentration is around 100 nM in lymph, 200 nM in blood, 550 nM in 
platelet poor plasma, 1.0 μM in plasma and about 1.0-1.2 μM in platelet rich plasma101,103. 
This concentration gradient of S1P is vital for several physiological processes in the body 
such as lymphocyte migration and angiogenesis104. However, the bioactive concentration of 
S1P in plasma is around 10 nM, because almost 1/3 of S1P is bound to albumin and 2/3 
bound to HDL105.  
4.1.3 S1P signalling and its physiological implications 
Circulating S1P functions as a bioactive lipid that evokes cellular responses via binding to the 
G-protein coupled S1P receptors on the cell surface106. It was reported that S1P can also act 
as a secondary messenger to mobilize calcium release (Fig. 10). There are five different 
subtypes of G-protein coupled S1P receptors (S1PR1-5), which have S1P binding affinities in 
the nanomolar range (6 to 64 nM respectively). S1PR1 is coupled to the G protein subunit 
Gαi/o, whereas S1PR2 and S1PR3 are coupled to Gαi/o, Gαq and Gα12/13, and S1PR4 and S1PR5 
are coupled to Gαi/o and Gα12/13106. Activation of S1PR evokes downstream signalling and 
cellular responses such as proliferation and migration (Fig. 11). Studies indicate that S1P also 
plays important roles in several cellular processes, including regulating cell differentiation, 
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survival and apoptotic process107. In addition, S1P contributes to angiogenesis during the 
embryonic development phase and the maintenance of vasculature integrity. The 
concentration gradients of S1P in the body also help control lymphocyte migration processes, 
supporting a role of S1P in inflammation and the immune system. Immuno-modulating drugs 
such as Fingolimod and Ozanimod that were designed to target S1PR receptors cause S1PR1 
internalisation to treat multiple sclerosis108. S1PR1 was also reported to be involved in tumour 
cell growth. Activation of S1PR1 by exogenous S1P results in downstream signalling of ERK 
and activation of the PI3K-Akt-Rac pathway, thereby amplifying tumour cell proliferation and 
metastasis109 (Fig. 11). Activating S1PR1 greatly enhanced the ability of ovarian cancer cells 
to invade the ovary. Moreover, the proliferative effect of S1P on endothelial cell also facilitates 
angiogenesis around the tumour110.  
  
Figure 11. Schematic diagram showing downstream signalling pathways of G-protein coupled 
sphingosine-1-phosphate receptor subtypes. AC: adenylyl cyclase; ERK: extracellular signal-
regulated kinases; PLC: phospholipase C; PI3K: phosphoinositide 3-kinase; Akt: Protein kinase B; Rac: 
Ras-related C3 botulinum toxin substrate; Rho: Ras homolog gene family; Cdc42: cell division control 
protein 42 homolog; JNK: c-Jun N-terminal kinase. Figure adapted from Isphingo111.  
Changes in circulating S1P concentrations or S1P signalling have been reported to be 
associated with many diseases and clinical implications. For instance, increased serum S1P 
concentrations were found in patients with inflammatory disease and ovarian cancer112 . 
Recent research suggest that S1P also relates to the development of atherosclerosis, 
diabetes and neurodegeneration 113 . Due to the majority of S1P being bound to HDL, 
alterations in HDL level or dysfunction of HDL may disrupt the HDL-S1P interactions resulting 
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in increased free bioavailable S1P concentrations. Studies have found lower HDL-S1P 
interactions and elevated plasma S1P concentrations in patients with heart disease, diabetes 
and obesity105. Elevated bioavailable S1P can signal through the S1P receptors, which may 
result in amplified cellular responses. Moreover, there is evidence to indicate that S1P is 
involved in blood coagulation pathway, with elevated S1P concentrations stimulating 
endothelial cell release of coagulation Factor Xa thereby accelerating thrombin production114. 
In addition, it has been reported that elevated circulating S1P concentrations are linked to the 
development of angiotensin II-induced hypertension115.  
4.1.4 S1P and platelet function; many questions need to be addressed. 
As previously described, intracellular cellular S1P concentrations are kept low by SPP and 
SPL enzymes. However, platelets lack of both SPP and SPL to degrade S1P, but also exhibit 
constitutive high sphingosine kinase activity. Hence, platelets can produce and store a large 
amount of S1P 116 . Studies have demonstrated that thrombin-mediated PAR receptor 
activation can induce S1P synthesis and release from platelets117. In addition, TxA2 and ADP 
also cause S1P release from platelets, which can be blocked by aspirin118. S1P can affect 
local endothelial cell responses resulting in elevated tissue factor, chemokines and growth 
factor release119. A study suggest that S1P can synergize with thrombin to promote the blood 
coagulation process54. However, there are many controversies in the literature about S1P 
synthesis, release by platelets and whether the endogenous S1P can affect platelet function. 
Urtz et al54 showed that sphingosine kinase 2 is the major isoform of SphK in mouse platelets 
and responsible for platelet S1P synthesis, inhibition of SphK2 greatly reduced platelet 
aggregation. This is concurrent with mouse platelet transcriptome data, where SphK1 is much 
lower than SphK2 (RPKM= 0.18 vs 4.83). In contrast, Münzer et al120 claims that SphK1 
negatively regulates mouse platelet function and knock out SphK1 significantly promoted 
platelet function. The effects of Sphingosine kinases in human platelets is largely unknown, 
transcriptome data indicate the mean RPKM of SphK1 is about 24.7 in human platelets, which 
is much higher than SphK2 (RPKM = 0.5) expression levels. Furthermore, the mechanism of 
release of S1P from activated platelet is also controversial. Current studies propose S1P can 
be released in two ways: a readily exchangeable and ATP dependent way near the cytosolic 
membrane for the de novo synthesized S1P release, and an alpha granule release mediated 
exocytosis dependent way which requires platelet activation. Jonnalagadda et al 121 
demonstrated that S1P release is primarily mediated by granule release and the SNARE 
complex is required, which Munc13-4 KO showed defective S1P release.  However, many 
research groups recognise S1P is transported out of the platelet via ATP binding cassette 
subfamily C member 4 (ABBC4) transporter 122 . Inhibition of this ABBC transporter by 
staurosporine or glyburide markedly diminished S1P release from thrombin activated 
platelets123. Furthermore, it was reported that platelets also express S1P receptors, therefore, 
platelet synthesized S1P might be able to signal in both autocrine and paracrine manner124. 
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However, the effects of S1P on platelet function and the S1P receptor subtypes expression 
are still largely unknown. Recent studies have demonstrated that S1PR1, S1PR2 and S1PR4 
receptors are expressed on both matured human and mouse megakaryocytes127. Moreover, 
S1PR1 receptor expression on megakaryocytes is essential for the formation of pro-platelet 
extension and release of platelets125. Knock out S1PR1 or S1PR4 receptor on megakaryocytes 
significantly reduced the number of pro-platelets formed and decreased the total platelet 
count in mouse models126. Conversely, activation of S1PR1 receptors on megakaryocytes 
increased platelet production127. No effect of KO S1PR2 was found. Based on platelets being 
derived from megakaryocytes, along with literature reports and S1P receptor transcriptome 
expression data in platelets (Fig. 5), I hypothesize that S1PR1, S1PR2, S1PR4 and S1PR5 
receptors are expressed on human platelets. 
The effect of S1P on platelet function is not clear and there are many contradictions between 
different studies. Yamamura et al 128  suggested that S1P can directly activate platelets 
causing shape change and aggregation, however, other studies oppose this finding. A whole 
blood study conducted by Urtz et al54 indicates that S1P produced by platelets directly controls 
platelet aggregation and potentiates coagulation via activation of the S1PR1 receptor on the 
platelets. Inhibition of S1PR1 reduced ADP or PAR4-AP induced aggregation. Moreover, it 
was reported that the S1PR2 receptor is involved in S1P-induced platelet aggregation and in 
patients with type II diabetes129. In contrast, work by Onuma et al85 demonstrated that S1P 
can inhibit platelet responses to CRP via the activation of S1PR4. However, most studies on 
S1P and platelets were conducted using supraphysiological concentrations of S1P (> 10 μM), 
which makes the relevance of the findings questionable. Previous work by García-Pacios et 
al130 indicated S1P exhibits an amphiphilic nature in Langmuir balance studies, in which S1P 
can be dissolved in aqueous buffer with a critical micelle concentration of 12 μM. Hence, S1P 
is the only sphingolipid that can dissociate into the cytosol from the phospholipid bilayer130. 
Theoretically, the highest S1P concentration can be delivered into an in vitro system is around 
12 to 14 μM, which further challenge current in vitro S1P studies using 20 to 40 μM non-
physiological concentrations. Moreover, there are no studies conducted on S1PR5 receptor 
expression on platelets. Furthermore, as a drug target, S1PRs agonist FTY720 (Fingolimod) 
has been approved by FDA and MEA in 2011 to treat multiple sclerosis, yet its potential effect 
on platelets is still not clear131. In order to clarify the effect of S1P on platelet function and 
probe the S1P receptor expression and signalling in platelets, along with discussions in 
Chapter 3, S1P was selected as the “novel platelet primer” to be carried forward for further 




4.1.5 Aims  
Previous experiments have found S1P can enhance PAR1-AP mediated platelet aggregation, 
however, the underlying mechanism of S1P priming of platelet function is still not clear. The 
aims of this part of the projects are therefore  
1. Investigate the effect of S1P on human platelets using functional and signaling assays. 
2. Demonstrate the signaling cascade and elucidate the mechanism of S1P priming. 
3. Identify S1P receptor subtypes expression on platelets and determine the effect of 
activating or inhibiting S1PRs. 
4. Examine the role of sphingosine kinases in platelet function 





4.2.1 A low concentration of S1P can enhance PAR-mediated aggregation 
To investigate S1P priming of platelet function, aggregation experiments were carried out by 
incubating human platelets in the presence or absence of 100 nM S1P for five minutes before 
stimulation with subthreshold (0.6-1.0 μM) or maximal concentrations (1.5-2.0 μM) of PAR1-
AP. Aggregation data indicated that 100 nM S1P can enhance platelet aggregation induced 
by low concentrations of PAR1-AP (Fig. 12A). The maximal aggregation was significantly 
increased from 13.1 ± 2.57% with PAR1-AP alone to 46.5 ± 6.29% in the presence of 100 nM 
S1P (Fig. 12Aii), also a 118% increase in the AUC was observed (Fig. 12Aiii). Note that Fig. 
12 A is the same figure shown in Fig. 6 D and has been included here for clarity. In contrast, 
high concentration PAR1-AP (1.5-2.0 μM)-induced maximal aggregation was only slightly 
increased in the presence 100 nM S1P (Fig. 12Bi-ii). No significant difference was found 
between maximum aggregations induced by PAR1-AP alone 60.7 ± 4.07% or in the presence 
of 100 nM S1P 64.1 ± 4.32% (Fig.12Bii). There was a 2% increase in the total AUCs 
(Fig.12Biii). In addition, no effect on platelet aggregation was observed with vehicle alone 
(0.2% methanol, data not shown). These data demonstrate that a low concentration of S1P 
can enhance PAR-mediated platelet aggregation. 
 
Figure 12. S1P enhances PAR1-AP induced platelet aggregation. Washed human platelets (2 × 
108/mL) were pre-incubated with vehicle (0.2% methanol) or 100 nM S1P for 5 minutes. Platelet 
aggregation were induced by subthreshold (0.6-1.0 μM) or maximal (1.5-2.0 μM) concentrations of 
PAR1-AP and recorded for 5 minutes. (A-B) (i) Representative traces of subthreshold and maximal 
aggregation induced by PAR1-AP in the absence or presence of 100 nM S1P. (ii) Histograms graph 
analysis of quantified percentage maximum aggregation induced by PAR1-AP alone or with the 
presence of S1P. (iii) Histograms graph analysis of AUCs induced by PAR1-AP alone or with the 
presence of S1P. AU: arbitrary unit. Data are plotted as mean ± standard error of the mean. Statistical 




4.2.2 High concentrations of S1P inhibit PAR-mediated aggregation 
Studies by Onuma et al85 found S1P can inhibit CRP-induced platelet aggregation at 10 to 40 
μM concentrations. To investigate the effect of higher concentrations of S1P, aggregation was 
induced by stimulating human platelets with a high concentration of PAR1-AP (1.5-2.0 μM) in 
the absence and presence of increasing concentrations of S1P. In the presence of 1 μM S1P, 
a small reduction platelet aggregation was observed (Fig. 13A). However, no statistical 
significance was found between maximum aggregation induced by PAR1-AP alone or in the 
presence of 1 μM S1P (Fig.13Aii), nor by measure the AUC (Fig. 13Aiii).  Platelet aggregation 
was however significantly reduced in the presence of 10 μM and 30 μM S1P (Fig. 13B-C). 
These findings indicate that high concentrations of exogenous S1P can suppress platelet 
aggregation. 
 
Figure 13. High concentrations of S1P inhibits PAR-induced platelet aggregation. Washed 
human platelets (2 × 108/mL) were pre-incubated with vehicle control (0.2% methanol) or high 
concentrations of S1P for 5 minutes. Platelet aggregation were induced by maximal concentration (1.5-
2.0 μM) of PAR1-AP and recorded for 5 minutes. (A-C) (i) Representative traces of maximal 
aggregation induced by PAR1-AP in the absence or presence of 1, 10, 30 μM S1P. (ii) Histograms 
graph analysis of quantified percentage maximum aggregation induced by high PAR1-AP alone or with 
the presence of high concentration S1P (1, 10, 30 μM). (iii) Histograms graph analysis of AUCs induced 
by high concentration PAR1-AP alone or with the presence of high concentration S1P (1, 10, 30 μM). 
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AU: arbitrary unit. Data are plotted as mean ± standard error of the mean. n=12. Statistical analysis: 
Student’s paired t-test. NS, no statistical significance; *** P < 0.001. 
 
4.2.3 Activation of S1P receptors by S1PRs pan-agonists results in enhanced 
platelet aggregation 
To investigate whether the S1P priming effect on platelet aggregation was mediated via the 
activation of S1P receptors, aggregation experiments were carried out by stimulating human 
platelets with subthreshold PAR1-AP in the presence of the pan-S1PR agonist DHS1P, 
FTY720 and FTY720-phosphate. The maximal aggregation increased from 19.4 ± 3.83% with 
PAR1-AP alone to 30.9 ± 4.32% in the presence of 1 μM DHS1P (Fig. 14Aii). There was a 
29% increase in the AUC, although this did not reach statistical significance (Fig. 14Aiii). In 
the presence of 1 μM FTY720, small increases were found in maximal aggregation and AUC, 
but no significance was found (Fig. 14B). In contrast, maximum aggregation was significantly 
increased from 18.5 ± 8.26% with PAR1-AP alone to 53 ± 10.9% in the presence of 1 μM 
phosphorylated FTY720 (Fig. 14Cii). The total aggregation was significantly increased by 89% 
measured as AUC (Fig. 14Ciii). These data suggest that activation of S1PRs by pan-S1PR 
agonists can enhance PAR-mediated platelet aggregation. However, DHS1P and FTY720 did 
not produce a similar degree of priming as 100 nM S1P or FTY720-P did, which might be due 






Figure 14. Pan-S1PR agonists enhance PAR-induced platelet aggregation. Washed human 
platelets (2×108/mL) were treated with vehicle control or S1PR agonist for 5 minutes. Platelet 
aggregation were induced by subthreshold (0.6-1.0 μM) concentration of PAR1-AP and recorded for 5 
minutes. (A-C) (i) Representative traces of PAR1-AP induced platelet aggregation in the absence or 
presence of 1.0 μM DHS1P, 1.0 μM FTY-720 or 1.0 μM FTY-720 phosphate .(ii) Histograms graph 
analysis of quantified percentage maximum aggregation induced by PAR1-AP alone or in presence of 
pan-S1PR agonists. (iii) Histograms graph analysis of AUCs induced by PAR1-AP alone or in the 
presence of S1PRs pan agonists. AU: arbitrary unit.  Data are plotted as mean ± standard error of the 





4.2.4 High concentration of S1PR agonists inhibit platelet aggregation 
To investigate whether the pan-S1PR agonists also exhibit a concentration dependent 
biphasic effect on platelet aggregation, human platelets were stimulated with a high 
concentration of PAR1-AP in the absence or presence of 10 μM DHS1P, 10 μM FTY720 or 
10 μM FTY720-phosphate. PAR1-AP mediated platelet aggregation was reduced in the 
presence of high concentrations of S1P receptor pan-agonists (Fig. 15).  These findings 
suggest the inhibitory effects induced by high concentrations of S1P are mediated via S1PRs. 
 
Figure 15. High concentration S1P receptor pan agonists inhibit PAR1-AP induced platelet 
aggregation. Washed human platelets (2×108/mL) were treated with vehicle control or S1PR agonist 
for 5 minutes. Platelet aggregation was induced by maximal (1.5-2.0 μM) concentrations of PAR1-AP 
and recorded for 5 minutes. (A) Representative traces of PAR1-AP induced platelet aggregation in the 




4.2.5 Activation of S1PR1 enhances PAR1-AP mediated platelet aggregation, 
whereas activation of S1PR4 and S1PR5 inhibits platelet aggregation.  
It is important to identify the S1PR subtypes expressed on human platelets and investigate 
which S1P receptor subtypes is mediating the effects of S1P on platelet function. Aggregation 
was induced by either subthreshold or maximal concentrations of PAR1-AP in the presence 
or absence of S1PR selective agonists. Aggregation experiments confirmed that activating 
S1PR1 can enhance PAR1-AP mediated platelet aggregation (Fig. 16Ai). In the presence of 
1 μM SEW2871, platelet maximal aggregation significantly increased from 7.67 ± 2.91% to 
34.5 ± 6.86% and the AUC was increased by 120% (Fig. 16Aii, Aiii).  
Aggregation experiments found there was no effect of activating S1PR2 or S1PR3 on PAR1- 
mediated platelet aggregation (Fig. 16Bi, Ci). Furthermore, no significant effect on maximal 
aggregation or AUC was observed in platelets pre-treated with 1 μM S1PR2 agonist CYM5520 
or 1 μM S1PR3 agonist CYM5541 (Fig. 16B and C). In addition, at 1 μM of concentration 
S1PR1, S1PR2 or S1PR3 agonists did not show inhibitory effects. However, further increases 
in the agonist concentration up to 10 μM occasionally resulted in inhibitory effects (data not 
shown). Activation of S1PR4 or S1PR5 receptors caused a strong inhibition of PAR1-mediated 
platelet aggregation (Fig. 16Di, Ei). The maximum aggregation induced by PAR1-AP was 
significantly decreased from 50.8 ± 7.58% to 3.25 ± 2.29% in the presence of 1 μM CYM50260 
(Fig. 16Dii) The AUC also decreased significantly as shown in (Fig. 16Diii). In the presence 
of 1 μM A971432, the maximal aggregation was reduced from 45 ± 6.72% to 4.2 ± 2.54% and 
there was a 79% decrease in the AUC (Fig. 16Eii, Eiii). The inhibitory effect of CYM50260 
and A971432 could be observed with lower concentrations starting at 0.1 μM and maximise 
at 1 μM. These observations suggest that S1PR1 is expressed on human platelets and 
responsible for the positive priming effect of submicromolar S1P. No effect was observed with 
S1PR2 agonist CYM5520 or S1PR3 agonist CYM5541 addition within a concentration range 
from 500 nM to 10 μM (data not shown), which suggest that S1PR2 and S1PR3 may not be 
expressed on human platelets.  In contrast, my data indicates that S1PR4 and S1PR5 are 
likely to be expressed on human platelets and responsible for the inhibitory effects induced 




Figure 16. Effect of S1PR selective agonists on PAR-mediated aggregation. Washed human 
platelets (2×108/mL) were treated with vehicle (0.2% DMSO) or S1PR agonists for 5 minutes. Platelet 
aggregation were induced by subthreshold (0.6-1.0 μM) or maximal (1.5-2.0 μM) concentrations of 
PAR1-AP and recorded for 5 minutes. (A-C) (i) Representative traces of platelet aggregation induced 
by subthreshold PAR1-AP in the absence or presence of the S1PR1 agonist SEW2871, S1PR2 agonist 
CYM5520 or S1PR3 agonist CYM5541. (D, E) (i) Representative traces of platelet aggregation induced 
by PAR1-AP in the absence or presence of the S1PR4 agonist CYM50260 or S1PR5 agonist A971432. 
(ii) Histograms graph analysis of quantified percentage maximum aggregation induced by PAR1-AP 
alone or in presence of S1P receptor agonists. (iii) Histograms graph analysis of AUCs induced by 
PAR1-AP alone or in the presence of S1P receptor agonists. AU: arbitrary unit. Data are plotted as 
mean ± standard error of the mean.  Statistical analysis: Student’s paired t-test. NS: no statistical 
significance; ** P < 0.01. 
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4.2.6 Antagonism of S1PR1 reduces PAR-mediated aggregation, whereas 
antagonism of S1PR4 enhances PAR-mediated aggregation.  
To investigate the effect of inhibiting S1PR subtypes, platelet aggregation was induced by 
subthreshold or high concentrations of PAR1-AP in the absence or presence of S1PR 
selective antagonists. Aggregation experiments determined that inhibition of S1PR1 inhibited 
PAR1-AP mediated platelet aggregation (Fig. 17Ai). In the presence of 0.1 μM Ex26, high 
concentration PAR1-AP induced platelet aggregation significantly decreased from 54.5 ± 11.9% 
to 14.5 ± 2.35% and the AUC was decreased by 61.1% (Fig. 17Aii, Aiii). Aggregation data 
indicated inhibition of S1PR2 or S1PR3 has no effect on subthreshold concentrations of PAR1-
AP mediated platelet aggregation (Fig. 17Bi, Ci). No significant effect on maximal aggregation 
or AUC was observed in platelets pre-treated with 0.1 μM S1PR2 antagonist JTE-013 or 1 μM 
S1PR3 antagonist TY52156 (Fig. 17Bii, Cii, Biii and Ciii). S1PR2 or S1PR3 antagonists did not 
show inhibitory effects on inhibiting platelet aggregation, however, further increasing the 
concentration of these antagonists up to 10 μM could resulted in some inhibitory effects (data 
not shown). Interestingly, another S1PR1 receptor antagonist W146 tested earlier in this study 
induced irreversible “aggregation” resulting in a maximal decrease in the light transmission 
just by itself (data not shown). We deduce that W146 might exhibit potential platelet lysis or 
toxic effect, thus it was excluded from the study. 
Antagonising S1PR4 using 1 μM CYM50358 hydrochloride enhanced subthreshold PAR1-AP 
mediated platelet aggregation (Fig. 17Di). The maximum aggregation was significantly 
increased from 9.4 ± 2.7% with PAR1-AP alone to 43.7 ± 7.68% in the presence of 1 μM 
CYM50358 hydrochloride (Fig. 17Dii) The total aggregation was significantly increased by 
81%, measured as AUC (Fig. 17Diii). This enhancing effect by antagonising S1PR4 is 
saturated at 1 μM, but it could start to be observed at lower concentration using 0.1 μM 
CYM50358 hydrochloride. 
These data are in line with result from S1P agonist tests, suggesting that S1PR1 is responsible 
for the positive priming effect of S1P. No effect was observed with addition of JTE-013 or 
TY52156, which strongly imply that S1PR2 or S1PR3 are not expressed in human platelets.  
Furthermore, S1PR4 antagonist enhanced PAR1-AP mediated aggregation, suggesting the 
inhibitory effect of supermicromolar S1P is partly mediated via S1PR4 activation and inhibition 
of S1PR4 could reverse this effect. However, due to the lack of commercially available S1PR5 




Figure 17. Effect of S1PR antagonists on PAR-mediated platelet aggregation. Washed human 
platelets (2×108/mL) were treated with vehicle (0.2% DMSO) or S1PR antagonists for 5 minutes. 
Platelet aggregation were induced by subthreshold (0.6-1.0 μM) or maximal (1.5-2.0 μM) 
concentrations of PAR1-AP and recorded for 5 minutes. (A-D) (i) Representative traces of PAR1-AP 
induced platelet aggregation in the absence or presence of S1PR1-4 antagonists: 0.1 μM Ex26 or JTE-
013, 1.0 μM TY52156 or CYM50358 hydrochloride. (ii) Histograms graph analysis of quantified 
percentage maximum aggregation induced by PAR1-AP alone or in presence of S1P receptor 
antagonists. (iii) Histograms graph analysis of AUCs induced by PAR1-AP alone or in the presence of 
S1P receptor antagonists. AU: arbitrary unit. Data are plotted as mean ± standard error of the mean.  
Statistical analysis: Student’s paired t-test. NS: no statistical significance; ** P < 0.01,  
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4.2.7 Inhibition of sphingosine kinases reduces PAR1-AP mediated platelet 
aggregation. 
To investigate the effect of inhibiting sphingosine kinases and endogenous S1P synthesis in 
platelets, aggregation was induced by high concentrations of PAR1-AP in the absence or 
presence of sphingosine kinase inhibitors. Aggregation experiments indicate that inhibition of 
sphingosine kinases can reduce PAR1-AP mediated platelet aggregation (Fig. 18Ai, Bi). In 
the presence of 1 μM SphK1 inhibitor PF543 hydrochloride, aggregation was significantly 
reduced from 50.3 ± 6.59% to 23.3 ± 8.7% (Fig. 18Aii) and the AUC was significantly reduced 
(Fig. 18Aiii).  In contrast, maximal aggregation induced by high concentrations of PAR1-AP 
was significantly reduced from 57.5 ± 5.6% to 4.25 ± 1.97% in the presence of 10 μM non-
selective SphK1/2 inhibitor DMS (Fig. 18Bii) and total aggregation was decreased by 83.6% 
(Fig. 18Biii). The inhibitory effect of DMS can be observed at 1 μM concentration (Fig. 18Bi). 
In contrast, further increasing PF543 hydrochloride concentration up to 10 μM did not produce 
the same degree of inhibition as 10 μM DMS did. These findings demonstrate that 
sphingosine kinases play a role in platelet aggregation, possibly via the control of de novo 
S1P synthesis and subsequent autocrine activation on the S1PR1 receptor. Furthermore, the 
non-selective SphK inhibitor DMS (IC50=500 nM) induced a much stronger inhibitory effect on 
platelet aggregation than the same concentration of the SphK1 selective inhibitor PF543 
hydrochloride (IC50=2 nM). This finding agrees with Urtz et al54 suggesting that SphK2 might 





Figure 18. Inhibiting sphingosine kinases reduces PAR1-AP induced platelet aggregation. 
Washed human platelets (2 × 108/mL) were pre-incubated with vehicle control (0.2% DMSO) or 
sphingosine kinase inhibitors for 5 minutes. Platelet aggregation were induced by maximal (1.5-2.0 
μM) concentration of PAR1-AP and recorded for 5 minutes. (Ai, Bi) Representative traces of maximal 
concentration PAR1-AP induced platelet aggregation in the absence or presence of 1.0, 10 μM SPHK1 
inhibitor PF543 hydrochloride or 1 μM, 10 μM SPHK1/2 inhibitor DMS (N, N-Dimethylsphingosine) 
respectively. (A, Bii) Histograms graph analysis of quantified percentage maximum aggregation 
induced by PAR1-AP alone or with the presence of 1 μM PF543 hydrochloride or 10 μM DMS. (A, Biii) 
Histograms graph analysis of AUCs induced by PAR1-AP alone or with the presence of SPHK 
inhibitors. AU: arbitrary unit. Data are plotted as mean ± standard error of the mean. Statistical analysis: 




4.3.1 Dual effect of S1P on integrin activation and P-selectin exposure. 
To investigate the underlying mechanism of how S1P affects platelet function in a 
concentration dependent biphasic manner, flow cytometry was carried out to exam the effects 
of S1P on PAR1-AP induced platelet integrin αIIbβ3 activation and P-selectin exposure (as a 
measure of -granule secretion). FACS analysis experiments indicate that PAR1-AP 
mediated integrin αIIbβ3 activation was significantly increased in the presence of 100 nM S1P, 
and the maximal integrin αIIbβ3 activation was increased from 1522 ± 75.5 to 1768 ± 79.3 (Fig. 
19Ai). In addition, the PAR1-AP concentration response curve (blue trace) was shifted to the 
left in the presence of 100 nM S1P (red trace), with the LogEC50 value significantly decreased 
from -5.59 ± 0.045 to -5.66 ± 0.027 (Fig. 19Aii). PAR1-AP mediated P-selectin exposure was 
also significantly increased in the presence of 100 nM S1P with maximal P-selectin exposure 
being increased from 5991 ± 192 to 6374 ± 152 (Fig. 19Bi). In addition, the PAR1-AP 
concentration response curve was shifted to the left with a reduction in the LogEC50 value 
(Fig. 19Bii).  
In contrast, PAR1-mediated integrin αIIbβ3 activation was significantly reduced in platelets pre-
treated with 10 μM S1P (Fig. 19Ci), with maximal integrin αIIbβ3 activation decreased from 
1550 ± 68.5 to 1238 ± 62.6 (Fig. 19Ci).  In addition, there was a slight rightward shift in the 
PAR1-AP concentration response curve, and LogEC50 value was increased from -5.57 ± 
0.023 to -5.54 ± 0.042 (Fig. 19Cii). PAR1-AP mediated P-selectin exposure was significantly 
decreased in the presence of 10 μM S1P. Maximal P-selectin exposure reduced from 6387 ± 
177 to 5869 ± 242 (Fig. 19Di) and the LogEC50 value of the PAR1-AP concentration response 
curve increased from -5.46 ± 0.019 to -5.44 ± 0.036 (Fig. 19Dii) in the presence of S1P. 
Therefore, it can be deduced that the biphasic effect of S1P on PAR1-AP mediated platelet 





Figure 19. S1P alters PAR1-mediated integrin activation and P-selectin exposure. Washed 
human platelets (2 × 107/mL) were incubated with vehicle (0.2% methanol) or S1P (100 nM, 10 μM, 10 
min), before stimulation with PAR1-AP for 10 minutes in the presence of fluorescently conjugated 
antibodies against the activated form of integrin IIb3 and P-selectin. Platelet samples were fixed (1 % 
PFA) before reading on a flow cytometer. (A and C) Platelet integrin activation level was measured by 
binding of PAC-1 antibody. Results are expressed as medium fluorescent intensity. (B and D) Platelet 
P-selectin exposure. Results are expressed as median fluorescent intensity. AU: arbitrary unit. N=10. 
Statistical analysis: two-way ANOVA with Bonferroni post hoc multiple comparisons. * P < 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001 (ii) Histograms graph analysis of the LogEC50 value measured of 
the PAC-1 and CD62P binding curve. Statistical Analysis: Student’s paired t-test. Data are plotted as 
mean ± standard error of the mean. NS: no statistical significance; * P < 0.05. 
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4.3.2 Effect of pan-S1PR agonists on integrin activation and P-selectin 
exposure. 
To further investigate effects of activating S1P receptors, FACS analysis was carried out to 
examine the effect of pan-S1PR agonists on PAR1-AP induced integrin αIIbβ3 activation and 
P-selectin exposure. FACS analysis indicate that PAR1-AP mediated integrin αIIbβ3 activation 
level was significantly increased in the presence of 1 μM phosphorylated FTY720 (Fig. 20Ai). 
Maximal integrin αIIbβ3 activation increased from 1281 ± 78.6 to 1419 ± 96.4, and the LogEC50 
value decreased from -5.52 ± 0.047 to -5.58 ± 0.049. However, no significance change in P-
selectin exposure was found (Fig. 20Aii).  In the presence of 1 μM DHS1P, a slight leftward 
shift in the PAR1-AP response curve was found, but no significant change in platelet integrin 
αIIbβ3 activation or P-selectin exposure level was found (Fig. 20 Bi, Bii). From these data 
obtained, it can be concluded that both activation of S1PRs and the downstream intracellular 
effects are required to affect integrin αIIbβ3 activation.  
 
Figure 20. Effect of pan-S1PR agonists on PAR1-mediated integrin activation and P-selectin 
exposure. Washed human platelets (2 × 107/mL) were pre-treated with vehicle or pan-S1PR agonist 
(10 min), before stimulation with PAR1-AP for 10 minutes in the presence of fluorescently conjugated 
antibodies against the activated form of integrin IIb3 and P-selectin. Samples were fixed (1 % PFA) 
before reading on a flow cytometer. (Ai, Bi) Integrin activation. (Aii, Bii) P-selectin exposure. Results 
are expressed as median fluorescent intensity. Data are plotted as mean ± standard error of the mean. 
N=3. Statistical analysis: two-way ANOVA with Bonferroni post hoc multiple comparisons. NS: no 




4.3.3 Activating or inhibiting S1PR1, S1PR4 and S1PR5 affects integrin activation 
and P-selectin exposure 
To demonstrate the mechanism of action of S1PR selective agonists and antagonists on 
platelet function, FACS analysis was carried out. As shown in Fig. 21A, maximal integrin αIIbβ3 
activation was significantly increased from 1266 ± 56 to 1361 ± 79 in the presence of 1 μM 
SEW2871, with no significant change in P-selectin exposure. In contrast, the integrin 
activation level of platelets pre-treated with 1 μM Ex26 remained unchanged (Fig. 21B). But 
a slight decrease in P-selectin exposure level (6956 ± 392.5 to 6656 ± 358.8) was observed 
(Fig.21Bii). Surprisingly, the S1PR4 agonist CYM50260, which strongly inhibited platelet 
aggregation, caused a significant increase (1266 ± 56.1to 1389 ± 84.0) in integrin αIIbβ3 
activation, but not P-selectin exposure (Fig. 21Ci, Cii).  In the presence of 1 μM S1PR4 
antagonist CYM50358 hydrochloride, the 3 μM PAR1-AP induced integrin activation and P-
selectin exposure was significantly increased from 732 ± 149 to 977 ± 224 (asterisk point, Fig. 
21Di). In addition, both curves were slightly shifted to the left. In contrast, the S1PR5 agonist 
A971432, which strongly inhibited platelet aggregation, reduced both integrin activation and 
P-selectin exposure levels (Fig. 21E). These findings indicate that activation of S1PR1 results 
in elevated integrin αIIbβ3 activation and priming of platelet function. Inhibition of S1PR4 
receptor increases both integrin αIIbβ3 activation and P-selectin exposure. The inhibitory effect 






















Figure 21. Effect of S1PR selective agonists and antagonists on PAR-mediated integrin 
activation and P-selectin exposure. Washed human platelets (2 × 107/mL) were pre-treated with 
vehicle or S1PR selective agonist/antagonist (10 min), before stimulation with PAR1-AP for 10 minutes 
in the presence of fluorescently conjugated antibodies against the activated form of integrin IIb3 and 
P-selectin. Samples were fixed (1 % PFA) before reading on a flow cytometer. (Ai - Ei) Integrin 
activation. (Aii - Eii) P-selectin exposure. Results are expressed as median fluorescent intensity. Data 
are plotted as mean ± standard error of the mean. N=3. Statistical analysis: two-way ANOVA with 
Bonferroni post hoc multiple comparisons. NS: no statistical significance. * P < 0.05, ** P < 0.01, *** P 




4.4.1 S1P induces PKB phosphorylation in a concentration dependent 
biphasic manner 
To investigate the downstream signaling elicited by S1P in platelets and probe the mechanism 
of S1P priming, the phosphorylation of the PI3K effector PKB (Akt-S473) and MAPK ERK1/2 
was determined by immunoblotting. S1P alone induced PKB phosphorylation (Fig. 22A). Both 
100 nM and 300 nM S1P evoked significant increases of 321% and 318% in PKB 
phosphorylation compare to vehicle (Fig. 22Bi). Further increasing the concentration of S1P 
resulted in less PKB phosphorylation, with the PKB phosphorylation levels reduced back to 
basal levels in the presence of 30 μM S1P (Fig. 22Bi). In addition, S1P alone did not induce 
any ERK1/2 phosphorylation (Fig. 22A,) and there was no significance found (Fig. 22Bii). A 
similar trend was observed in for phospho-PKC substrate phosphorylation levels (data not 




Figure 22. S1P induced phosphorylation of the PI3K effector PKB but not the MAPK ERK1/2. 
Washed human platelets (4 × 108/mL) were treated with vehicle (0.2% methanol) or S1P (10 nM to 30 
μM) or 5.0 μM PAR1-AP for 5 minutes at 37 °C. (A) Platelet lysates were subjected to SDS-PAGE 
followed by immunoblotting to measure the phosphorylation of PKB/AktS473 and pERK1/2Thr202/Tyr204. 
Immunoblotting for talin was used as a loading control. (Bi, ii) Histograms graph quantification of 
PKB/AktS473 and ERK1/2Thr202/Tyr204 phosphorylation level using LI-COR Image Studio Version 5.2. 
Results were normalized as fraction to the 5.0 μM PAR1-AP band and expressed in 1 arbitrary unit. 
N=7. Data are plotted as mean ± SEM. N=8. Statistical analysis: one-way ANOVA with Dunnett's test. 





Sphingosine-1-phosphate stimulated a transient increase in PKB phosphorylation (Fig. 23). 
pAktS473 was observed at 0, 1 and 2-minute incubation. Significant increases in PKB 
phosphorylation level were observed following a 3 minute or 5 minute incubation with 100 nM 
S1P (Fig. 23A, B).  In contrast, S1P-mediated PKB phosphorylation was reduced after a 
prolonged (10- or 30-minutes) incubation (Fig.23A, B). Therefore, platelets were incubated 
with S1P for 5 minutes in all following immunoblotting experiments.  
 
Figure 23. Kinetics of S1P induced PKB phosphorylation. Washed human platelets (4 × 108/mL) 
were treated with vehicle control (0.2 % methanol) or 100 nM S1P (0 - 30 min, 37 °C). (A) Platelet 
lysates were subjected to SDS-PAGE, followed by immunoblotting to measure the phosphorylation of 
PKB/AktS473. Immunoblotting for talin was used as a loading control. (B) Histogram of quantification of 
PKB/AktS473 phosphorylation. Quantification was performed using LI-COR Image Studio Version 5.2. 
Results were normalized to the amount of phosphorylation elicited by PAR1-AP. Data are plotted as 
mean ± SEM. N=4. Statistical analysis: one-way ANOVA with Dunnett's test. NS: no statistical 




4.4.2 Additive effect of S1P on PAR1-induced PKB and ERK1/2 phosphorylation. 
To investigate how S1P can prime PAR1-AP mediated platelet function, the phosphorylation 
levels of PKB and MAPK ERK1/2 were studied. Stimulation with PAR1-AP alone induced an 
increase in PKB phosphorylation (1417 ± 303) compared to the basal group (404 ± 71.4). In 
the presence of 10 nM, 30 nM, 100 nM and 300 nM S1P, 2.0 μM PAR1-AP induced PKB 
phosphorylation was increased from 1417 ± 303 to 1683 ± 409, 2088 ± 528, 1861 ± 400 and 
1708 ± 417 respectively (Fig. 24A,B).  In the presence of 1 μM S1P, PKB phosphorylation 
was 1552 ± 364, which was similar with to that induced by 2.0 μM PAR1-AP. In contrast, 
further increasing in the S1P concentration resulted in a decrease in PAR1-AP mediated PKB 
phosphorylation (Fig. 24A). In the presence of 3 μM, 10 μM and 30 μM S1P, the PKB 
phosphorylation level  were decreased to 1084 ± 249, 1098 ± 254 and 616 ± 142 respectively 
(Fig. 24Bi). 
Previous experiments indicated that S1P did not induce ERK phosphorylation by itself. 
Platelets stimulation with 2.0 μM PAR1-AP resulted an increase in ERK1/2 phosphorylation 
level from basal of 647 ± 108 to 1318 ± 252 (Fig. 24A). This PAR1-AP induced ERK 
phosphorylation was further enhanced in the presence of 10 nM and 30 nM S1P to 1573 ± 
331 and 1856 ± 319, respectively.  In the presence of 100 nM S1P, a maximal 61% increase 
in ERK1/2 phosphorylation (2124 ± 325) was observed in comparison to 2.0 μM PAR1-AP 
alone (1318). However, at higher S1P concentrations the increase in pERK became less 
apparent. In the presence of 300 nM, 1 μM, 3 μM and 10 μM S1P, PAR1-AP induced ERK1/2 
phosphorylation was 1706 ± 197, 1758 ± 272, 1724 ± 264 and 1422 ± 258 respectively (Fig. 
24Bii). In contrast, the highest S1P concentration tested (30 μM) reduced PAR1-AP induced 






Figure 24. Concentration dependent biphasic effect of S1P on PAR1-AP induced PKB 
phosphorylation. Washed platelets (4 × 108/mL) were pre-treated with vehicle or S1P (10 nM - 30 
μM, 3 min) before stimulation with PAR1-AP (2.0 μM, 37 °C). (A) Platelet lysates were subjected to 
SDS-PAGE, followed by immunoblotting to measure the phosphorylation of PKB/AktS473. 
Immunoblotting for talin was used as a loading control. (Bi, ii) Histograms of quantification of 
PKB/AktS473 and ERK1/2Thr202/Tyr204 phosphorylation. Quantification was performed using LI-COR 
Odyssey Image Studio Version 5.2. N=7. Data are plotted as mean ± SEM. Statistical analysis: one-




The immunoblotting results indicate that S1P activates the PI3kinase pathway. To evaluate 
the role of PI3kinase in S1P mediated priming, we incubated platelets with the pan-PI3K 
inhibitor wortmannin. As shown in Fig.25, 100 nM S1P increased PKB phosphorylation from 
a basal level of 434 ± 24.3 to 706 ± 102. In the presence of 100 nM wortmannin, both the 
basal and S1P-stimulated PKB phosphorylation induced by 100 nM S1P was reduced to 312 
± 31.5 and 436 ± 52.3 respectively (Fig.25Bi).  
An additive effect was observed in the presence of both PAR1-AP and S1P, as  PKB 
phosphorylation induced by PAR1-AP alone (1476 ± 294) was increased to 1752 ± 393 in the 
presence of S1P (Fig.25A, Bi). Wortmannin, reduced PKB phosphorylation induced by PAR1-
AP and the combination of both PAR1-AP and S1P to 632 ± 525 to 525 ± 124, respectively 
(Fig.25A, Bii). 
Basal ERK phosphorylation was 426.3 ± 31.4 and changed to 604 ± 118 in the presence of 
100 nM S1P. Wortmannin reduced basal and S1P-stimulated ERK phosphorylation to 395 ± 
36.5 and 509 ± 40.4 respectively (Fig.25Bi). An additive effect was observed, as the ERK1/2 
phosphorylation with by PAR1-AP alone 2007 ± 481 was increased to 2397 ± 683 in the 
presence of both PAR1-AP and S1P (Fig. 25A, Bii). Wortmannin reduced, ERK1/2 
phosphorylation induced by 2.0 μM PAR1-AP and a combination of both PAR1-AP and S1P 
(Fig. 25A, Bii). The results suggest that the additive effects of S1P on PAR1-AP induced PKB 




Figure 25. Role of PI3K in S1P and PAR1-AP mediated PKB phosphorylation. Washed platelets 
(4 × 108/mL) were pre-treated with vehicle or wortmannin (100 nM), before incubation with vehicle or 
S1P (100 nM) prior to stimulation with PAR1-AP (2.0 μM, 37 °C). (A) Platelet lysates were subjected 
to SDS-PAGE, followed by immunoblotting to measure the phosphorylation of PKB/AktS473 and ERK1/2, 
Immunoblotting for talin was used as a loading control (Bi, ii) Histograms of quantification of 
PKB/AktS473 and ERK1/2Thr202/Tyr204 phosphorylation. Quantification was performed using LI-COR 
Odyssey Image Studio Version 5.2. Data are plotted as mean ± SEM. N=6. Statistical analysis: two-
way ANOVA with Bonferroni post hoc multiple comparisons. NS: no statistical significance. * p<0.05, 




4.4.3 S1P supresses PGE1-mediated VASP phosphorylation  
To investigate the downstream signalling cascade of S1P receptors and probe the receptors 
coupling in platelets, the phosphorylation level of the vasodilator-stimulated phosphoprotein 
(VASP) were studied. VASP is a downstream effector of the cAMP-dependent pathway that 
abundantly expressed in platelet. Activation of adenylyl cyclase (AC) will result in cyclic 
adenosine monophosphate (c-AMP) production, c-AMP then activate downstream protein 
kinase A (PKA) which then phosphorylates VASP on the serine157 or serine239 residue. For 
instance, activation of Gαs coupled prostacyclin receptor by PGE1 activate AC and c-AMP 
pathway, which cause downstream VASP phosphorylation. In contrast, activating the Gαi/o 
coupled P2Y12 receptor by ADP reduce VASP phosphorylation. Therefore, an increase in 
VASP phosphorylation level indicates activation of Gαs coupled receptor and Vice Versa.  
In order to investigate whether S1P receptors have as Gαs coupled signalling component, 
platelets were treated with increasing concentrations of S1P and 100 nM PGE1 was used as 
a positive control, the phosphorylation level of VASP-serine239 was examined by 
immunoblotting. 100 nM PGE1 was used as a positive control.  In the presence of 100 nM 
PGE1, the VASP serine239 phosphorylation level increased from 964 ± 205 to 14670 ± 3472 
(Fig.26Ai, Aii). In contrast, increasing concentrations of S1P did not induce VASP 
phosphorylation compared to the vehicle control group (Fig.26Aii). Therefore, there is no 
evidence that supports Gαs coupling of the receptors. 10 μM and 30 μM S1P did not induce 
VASP phosphorylation, although platelet aggregation was strongly inhibited in the presence 
of these concentration of S1P. Hence, high concentration S1P inhibiting platelet function is 
not mediated via activation of Gαs coupled GPCR. 
In contrast, a decrease in VASP phosphorylation level was found when platelets were co-
stimulated treated with 20 μM ADP and 100 nM PGE1 co-stimulation (2310 ± 525), in 
comparison to the vehicle group (13940 ± 2884) stimulated by 100 nM PGE1 alone (Fig. 26B).  
This indicates that activation of Gαi/o coupled P2Y12 receptor by ADP can reduce PGE1 
mediated VASP phosphorylation. Similarly, decreases in VASP phosphorylation were level 
observed in platelets treated with PGE1 and S1P. PGE1-stimulated pVASP-S239 was 
decreased from 13940 ± 2884 to 10110 ± 4933 in the presence of 100 nM S1P (Fig. 26B). A 
similar in pVASP-S239 was also found in the presence of 10 nM, 30 nM, 300 nM and 1 μM 
S1P. Interestingly, the pVASP-S239 level was reduced to 11156 ± 3565 and 7913 ± 3164 in 
the presence of 10 μM and 30 μM S1P respectively, although at these concentrations S1P 
strongly inhibited platelet aggregation. These data indicate that S1P can signal via Gαi coupled 
receptors resulting in inhibition of cAMP production.  
The effect of S1PR selective agonists on VASPS239 was also examined by immunoblotting. 
S1P receptor selective agonists (10 nM - 10 μM) did not induce VASP phosphorylation (N=1, 
data not shown). This suggests that S1P receptor subtypes do not couple to Gαs in platelets 
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and support the finding that the inhibitory effect of high concentrations of S1P on platelet 
aggregation are not mediated via activation of Gs coupled receptors. 
 
 
Figure 26. Stimulation of platelets with S1P suppresses PGE1-mediated VASP phosphorylation. 
(A) Washed platelets (4 × 108/mL) were treated with vehicle (0.2% methanol, 5 min), S1P (1 nM - 30 
μM, 5 min) or PGE1 (100 nM, 3 minutes). Platelet lysates was subjected to SDS-PAGE, followed by 
immunoblotting to measure the phosphorylation of VASPS239. Immunoblotting for talin was used as a 
loading control. (ii) Histograms of quantification of VASPS239. (B) Washed platelets (4 × 108/mL) were 
stimulated with PGE1 (100 nM) in the presence of S1P (1 nM – 30 μM) or ADP (20 μM). Platelet lysates 
were subjected to SDS-PAGE, followed by immunoblotting to measure the phosphorylation of 
VASPS239. Immunoblotting for talin was used as a loading control. (ii) Histograms of quantification of 
VASPS239.  Quantification was performed using LI-COR Odyssey Image Studio Version 5.2. N=4. 
Statistical analysis: one-way ANOVA with Dunnett's test. NS: no statistical significance. * p<0.05, *** p 




4.5.1 PAR1-AP mediated platelet calcium mobilization is not altered by S1P 
Several studies have indicated that S1P can mobilize intracellular calcium release by 
activating S1P receptors, or act as a intracellular secondary messenger to directly cause 
calcium flux132. To explore whether S1P can modulate platelet calcium mobilization function, 
Ca2+ mobilization assays were carried out to exam the effect of S1P on PAR-induced platelet 
calcium flux. Platelets loaded with the cell permeant calcium indicator, Fura-2 AM were pre-
treated with S1P before stimulation with PAR1-AP. The level of calcium mobilization was 
measured as the total area under the relative fluorescence units (RFU) curve. High 
concentration of PAR1-AP induced a large RFU curve result in a bigger AUC (Fig. 27Ai). 
Interestingly, S1P alone did not induce calcium release in human platelets with a 
concentration range from 10 nM to 10 μM tested (Fig. 27Aii). 
In the presence of 100 nM S1P, a slight increase in the total calcium mobilization level was 
observed (Fig. 27B). In contrast, platelet calcium mobilization was reduced in the presence 
of 10 μM S1P, the maximal calcium flux was decreased from 35.9 ± 3.03 to 34 ± 3.12. A 
rightward shift on the curves was observed, which the LogEC50 increased from 6.102 ± 0.17 
to -6.009 ± 0.16. Since S1P did not directly induce calcium release or facilitate PAR1-AP 
mediate calcium mobilization, it can be deduced that there is no Gαq coupled S1P receptor 
signalling in platelets, thus further confirming there is no Gαq coupled S1PR2 or S1PR3 
expression. Moreover, these findings contradict the studies suggesting that S1P can act as 






Figure 27. Effect of S1P on PAR-mediated calcium mobilization. (A) Washed platelets (2 × 108/mL) 
loaded with Fura2-AM in the presence of 1 mM CaCl2 were stimulated with PAR1-AP or S1P. (i) 
Representative traces of PAR1-AP mediated calcium mobilization, measured as change in 340/380 
nm excitation ratio. (ii) Representative traces of S1P mediated calcium mobilization. (B) Washed 
platelets (2 × 108/mL) loaded with Fura2-AM in the presence of 1 mM CaCl2 were pre-incubated with 
either vehicle (0.2% methanol) or S1P (5 min) before stimulation with PAR1-AP. (i) PAR1-AP 
concentration response in the absence and presence of 100 nM S1P. (ii) PAR1-AP concentration 
response in the absence and presence of 10 μM S1P. Results are expressed as either R.F.U or A.U.C. 
Data are plotted as mean ± standard error of the mean. N=3. Statistical analysis: two-way ANOVA with 




4.5.2 S1P has no effect on PAR1-AP mediated TxA2 production 
As previously described, TxA2 plays an important role in platelet function and thrombus 
formation, with its production being the target of the antiplatelet therapy, aspirin. Ulrych et 
al107 have suggested that S1P can signaling through ERK1/2 pathway and that there are close 
interactions between S1P production and TxA2 synthesis.  To gain insight of how S1P can 
enhance platelet function we explored the possibility that S1P could enhance PAR1-AP 
mediated TxA2 production. TxB2 ELISA assays were carried out to evaluate the PAR1-AP 
induced TxA2 production in the absence or presence of 100 nM S1P at non-stirring condition.  
A logarithmic standard curve was generated from TxB2 standard samples (Fig.28Ai).  
In the absence of PAR1-AP, no significant difference was found between the vehicle group 
(2.31 ± 0.355 ng/mL) and 100 nM S1P treated (2.93 ± 0.469 ng/mL) platelets. In contrast, 
there was an 11% increase in 1 μM PAR1-AP induced TxA2 production between vehicle 
control (83. 8 ± 13.1 ng/mL) and 100 nM S1P treated (93.4 ± 14.1 ng/mL) group, although 
this did not reach significance. These data demonstrate that S1P did not directly induce TxA2 
synthesis, which is in line with the S1P induced pERK phosphorylation data. However, it is 
still possible that S1P can potentiate PAR1-mediated platelet function via increases in TxA2 
synthesis. Additional experiments are required.  
 
Figure 28. Effect of S1P on PAR1-AP mediated platelet TxA2 production. Washed platelets (4 × 
108/mL) were incubated with 100 nM S1P (5 min) in prior to stimulation with 1 μM PAR1-AP (5 min) 
under non-stirring condition. The reaction was stopped by addition of 5 mM EDTA and 100 μM 
indomethacin. (i) A standard curve was used to determine concentrations of TxB2. (ii) Histogram of 
the concentration of TxB2 generated by S1P, PAR1-AP and S1P + PAR1-AP. Data are plotted as mean 
± standard error of the mean. N=7. Statistical analysis used was two-way ANOVA with Bonferroni post 




4.5.3 Activation of S1PR4 or S1PR5 and inhibition of sphingosine kinase reduces 
platelet spreading on fibrinogen. 
Recently, Gazit et al133 using sphingosine kinase knock-out mice demonstrated that S1P is 
required for both platelet aggregation and spreading. To investigate the role of S1P in platelet 
spreading, platelets in the presence of S1PR agonists, antagonists or a sphingosine kinase 
inhibitor were spread onto glass wells coated with 100 μg/mL fibrinogen and labelled by F-
actin specific fluorescent dye. The platelet average cell area was 11.8 ± 0.791 without 
fibrinogen stimulation (Fig. 29A). With stimulation by 100 μg/mL fibrinogen, platelet spread, 
and the average platelet cell area was increased to 15.9 ± 0.314 μm2 (Fig.29B). In addition, 
more platelets were found to be adhered to the 100 μg/mL fibrinogen coated wells than the 
no fibrinogen wells. 
In the presence of 1 μM FTY720-P, the average cell area remained unchanged (Fig. 29C). 
The average platelet cell size increased slightly to 16.58 ± 0.27 μm2 in the presence of 1 μM 
SEW2871 (Fig. 29D). In contrast, significant decreases in the average cell area were found 
in platelets treated with 1 μM S1PR4 agonist CYM50260, 1 μM S1PR5 agonist A971432 and 
1 μM SphK inhibitor DMS (Fig.29E, G, H and I).  with the average cell area decreased from 
15.9 ± 0.314 μm2 to 9.23 ± 0.21 μm2, 11.8 ± 0.306 μm2, and 11.2 ± 0.246 μm2 respectively 
(Fig. 29I). Platelets treated with CYM50260, A971432 or DMS small and changed to an 
elongated/triangular shape (Fig. 29E, G, and H). In addition, there were fewer platelets found 
per field of view. Surprisingly, there was no increase, but a slight decreased of the platelet 
average cell area (15.3 ± 0.32 μm2) in the presence the S1PR4 antagonist CYM50358 
hydrochloride (Fig.29F), which was the ligand that significantly enhanced platelet aggregation.  
These data suggest that the inhibitory effects of S1P are mediated via activation of the Gα12/13 
coupled S1PR4 and S1PR5 receptors, negatively regulating platelet morphological change. 
Studies have previously demonstrated that S1PR2, S1PR4 and S1PR5 receptors are the 
unique Gα12/13 coupled GPCRs that negatively regulate Rac activity134,135,136. Furthermore, the 
non-selective SphK inhibitor DMS also induced negative effects on platelet shape change, 
which suggest the intrinsically synthesized S1P play a role in regulating platelet function via 
controlling membrane polarity or cell morphology. This is concurrent with SphK KO mouse 
study demonstrated by Gazit et al133, and study on exogenous S1P increase membrane 




Figure 29. Platelet spreading on fibrinogen is inhibited by S1PR4, S1PR5 agonists and a SphK 
inhibitor. Washed platelets (7 × 107/mL) were incubated with vehicle (0.2% DMSO) or S1PR 
agonists/antagonists or the SphK inhibitor DMS (10 min). Platelets were then left to adhere onto a 96 
well glass bottom plate coated with 100 μg/mL fibrinogen (60 min, 37°C). Samples were fixed (1 % 
PFA) before permeabilisation (0.1% triton) and staining with ActinGreen 488 ReadyProbes reagent. 
(A) Resting/basal 3% BSA (B) vehicle-treated (C) 1 μM FTY720 phosphate (D) 1 μM SEW2871 (E) 1 
μM CYM50260 (F) 1 μM CYM50358 hydrochloride (G) 1 μM A971432 (H) 1 μM DMS. (I) Histogram 
displaying the average platelet area (μm2).  Three images were taken per well. Average cell area was 
measured from 50 cells, data are plotted as mean±SEM. N=3. Statistical analysis: One-way ANOVA 




4.5.4 Human platelet spreading is reduced by high concentrations of S1P. 
To investigate whether S1P affect fibrinogen induced spreading, human platelets treated with 
S1P were spread onto glass wells coated with 100 μg/mL fibrinogen and labelled by F-actin 
specific fluorescent dye. The platelet average cell area was 11.8 ± 0.791 μm2 without 
fibrinogen (Fig. 29A). Upon in contact with 100 μg/mL fibrinogen, the average platelet cell 
area was increased to 17.7 ± 0.256 μm2 (Vehicle control, 0.2% methanol).  In the presence of 
100 nM S1P, the average cell area was slightly increased to 18.2 ± 0.287 μm2 (Fig. 30E). In 
contrast, pre-treatment of platelets with either 1 μM or 10 μM S1P decreased the average 
platelet cell size to 15.56 ± 0.19 μm2 and 9.43 ± 0.29 μm2 (Fig. 30E).
 
Figure 30. Platelet spreading on fibrinogen is inhibited by 1 μM and 10 μM S1P. Washed platelets 
(7 × 107/mL) were incubated with vehicle (0.2% methanol) or S1P (100 nM, 10 μM) for 10 min. Platelets 
were then left to adhere onto a 96 well glass bottom plate coated with 100 μg/mL fibrinogen ( 60 min, 
37°C). Samples were fixed (1 % PFA) before permeabilisation (0.1% triton) and staining with 
ActinGreen 488 ReadyProbes reagent. (A) Vehicle control (B) 100 nM S1P (C) 1 μM S1P (D) 10 μM 
S1P (E) Histogram displaying the average platelet area (μm2). Data obtained from one experiment with 
three individual platelet donors. Three images were taken per well. Average cell area was measured 
from 50 cells, data are plotted as mean±SEM. N = 3. Statistical analysis: One-way ANOVA with 





In 10 μM S1P treated group, platelets shrunk and lost the spherical shape, with no cell 
protrusion and much less platelet-platelet interactions observed (Fig.30D). In addition, there 
were much smaller number of platelets found on the field of view. Interestingly, more 
platelet-platelet interacts in the 100 nM S1P or 1 μM S1P treated platelets and more cell 
protrusions were observed (Fig.30B, C). These data suggest high concentration S1P inhibit 
platelet function via negatively regulating the platelet spreading and adhesion process, 
possibly through activation of S1PR4 and S1PR5 receptors. 
4.6 Discussion  
This study has demonstrated for the first time that exogenous S1P can concentration-
dependently alter platelet function, with low concentrations of S1P priming platelet function 
and high concentrations of S1P inhibiting platelet responses. S1P enhanced PAR1-AP 
mediated platelet aggregation, integrin αIIbβ3 activation and P-selectin exposure. S1P did not 
affect PAR1-AP mediated TxA2 production nor calcium release in platelets.  
Based on the data obtained from aggregation experiments and FACS assays using S1P 
receptor agonist and antagonists, I suggest S1PR1, S1PR4 and S1PR5 receptor subtypes are 
expressed on human platelets, while I found no evidence to support S1PR2 or S1PR3 
expression. This study demonstrates activation of S1PR1 or inhibition of S1PR4 can enhance 
platelet function, while inhibition of S1PR1, activation of S1PR4 and S1PR5 reduce platelet 
responses, which suggest the concentration dependent biphasic effect of S1P is mediated 
via differential signalling through different S1P receptor subtypes. The positive priming effects 
of S1P might be mediated via activation of Gαi/o coupled S1PR1 receptor and downstream 
PI3K signalling pathway (Fig. 1). In contrast, the inhibitory effects of S1P may be mediated 
via activation of Gα12/13 coupled S1PR4 and S1PR5, resulting in negative regulation of 
cytoskeletal dynamics and potential inhibition of ERK. Furthermore, we found inhibition of 
sphingosine kinases reduced PAR1-AP mediated platelet aggregation and platelet spreading, 
suggesting de novo synthesized S1P plays an important role in controlling platelet activation 




Figure 31. Schematic diagram showing the hypothesized mechanism of S1P induced 
concentration dependent biphasic effects on PAR1-AP mediated platelet function. S1PR: S1P 
receptor; PAR1: protease-activated receptor 1; Rho: Rho family of GTPases; Rac: Ras-related C3 
botulinum toxin substrate; PIP2: phosphatidylinositol 4, 5-biphosphate; PIP3: phosphatidylinositol (3, 4, 
5)-triphosphate; PKB: protein kinase B. PLA2: phospholipase A2; Rap1b: Ras-related protein 1b. 
 
4.6.1 Activation of S1P receptors affects PAR1-AP mediated platelet function in 
a concentration dependent biphasic manner. 
S1P exerted a characteristic, concentration dependent biphasic effect on PAR-mediated 
platelet function. Platelet aggregation, integrin αIIbβ3 activation, P-selectin exposure, 
phosphorylation of AKT and ERK were enhanced in the presence of 100 nM S1P but inhibited 
in the presence of supermicromolar S1P. This is the first time the S1P biphasic effect has 
been observed in a platelet study. Similar S1P concentration dependent biphasic effects have 
previously been observed in other cell types. A study by Wang et al138 found the 0.5 - 2 μM of 
S1P stimulated in vivo ovarian cancer cell growth and migration, and this was inhibited by 5 
μM S1P and ablated by 20 μM S1P. Another study based on three different osteoblastic cell 
lines found significant increases in cell growth with 100 nM - 1 μM S1P but decreases in the 
presence of 5 μM139. Furthermore, S1P enhanced T cell migration at a concentration range 
from 1 - 100 nM but exerted inhibitory effects from 100 - 500 nM. Machida et al140 reported 
that S1P induced a biphasic effect on calcium release in vascular smooth muscle cell starting 
at 100 nM. As many studies reported, this biphasic effect may be due to differential signalling 
via S1P receptor subtypes, and the turning point concentration is dependent on the incubation 




Similar biphasic effects were also observed in platelets pre-incubated with the pan-S1PR 
agonist dihydro-S1P, FTY-720 and phosphorylated FTY-720. Dihydrosphingosine-1-
phosphate (DHS1P) is a synthetic analogue of S1P, a study by Bu et al141 indicate that DHS1P 
can activate the ERK1/2 pathway in fibroblasts. My data demonstrates that DHS1P (1 μM) 
induces a milder enhancement in platelet aggregation compared to S1P, this may be due to 
DHS1P having a lower binding affinity for the S1PRs and/or that it cannot evoke intracellular 
effects such as calcium mobilization142. No obvious effect of DHS1P on platelet integrin 
activation or P-selectin exposure was detected. Further increasing the DHS1P concentration 
resulted in platelet inhibition.   
FTY720 (Fingolimod) is a pro-drug used for treating multiple sclerosis, which is a synthetic 
analogue of sphingosine. FTY720 can be phosphorylated by sphingosine kinases to form 
FTY720-P which is able to activate S1PR1, 3, 4, 5 receptors. Aggregation data demonstrated 
that the FTY-720 only induced a mild increase in platelet aggregation. This agrees with 
previous findings by Ocwieja et al 143, who showed that oral treatment of Fingolimod could 
somewhat enhance ADP mediated platelet aggregation. In contrast, phosphorylated FTY720 
significantly promoted platelet aggregation. In addition, FTY720-P significantly potentiated 
platelet integrin αIIbβ3 activation. This is supported by a study demonstrating that FTY720-P 
enhanced chemokine induced calcium release and cell migration in hematopoietic stem 
cells144. Study by Anada et al145 has demonstrated that FTY720 can be phosphorylated in 
platelets to FTY720-P and transported out of the cell without platelet activation. However, this 
process is relatively slow as only 47 % of FTY720 was phosphorylated during a 1-hour 
incubation with 3 × 107 human platelets145. This may explain why FTY720 evoked a lesser 
effect than FTY720-P on platelet aggregation. Furthermore, it was reported that Fingolimod 
treatment can activate S1PR1 on mouse megakaryocytes resulted in increased platelet 
production127.  
4.6.2 S1P receptor subtypes expression on human platelets 
It is important to identify the S1PR subtypes expressed on platelets in future studies 
examining the role of S1P in regulating platelet function. It was reported that S1PR1, S1PR2 
and S1PR3 are widely expressed146, while S1PR4 is predominantly expressed in lymphoid 
tissue147 and S1PR5 expressed in spleen and the central nervous system148. Previously it was 
suggested S1PR1, S1PR2, S1PR4 and S1PR5 might be expressed in human platelets125, 126. 
Using the commercially available pharmacological tools listed in Table 1, platelet 
aggregations were carried out in the absence or presence of S1PR agonists and antagonists 
to probe the expression of S1P receptors on human platelets. Selective agonists and 
antagonists for the S1PR2 and S1PR3 were tested using a concentration range from 100 nM 
to 10 μM. However, no effect on platelet aggregation was observed with any of these ligands. 
This suggests that S1PR2 and S1PR3 are not expressed on human platelets, which is in line 
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with transcriptome expression data demonstrating that no mRNA transcript for S1PR2 or 
S1PR3 is in human platelets. In addition, calcium mobilization assays demonstrated that S1P 
alone or in combination with PAR1-AP does not modulate platelet calcium signalling. 
Suggesting that S1P is not binding to any S1PRs which couple to Gαq such as S1PR2 and 
S1PR3149. However, the S1PR2 agonist CYM5520 and S1PR3 agonist CYM5541 used in this 
study are allosteric agonists for their respective receptors and are the only ligands for these 
receptors commercially available. As shown in Table 1, these two compounds have a much 
lower binding affinity than the other S1PR agonists or the orthosteric ligand S1P. Studies by 
Satsu et al150  and Jo et al151  using receptor binding site mutation technique and ligand 
competitive assay have indicated these two compounds bind to different binding sites on the 
S1PR2 or S1PR3 receptor than the orthosteric ligand S1P. This binding affinity and binding 
site difference might result in signalling differences or functional bias. Therefore, to confirm 
the S1P receptor expression, immunoblotting experiments using S1PR2 and S1PR3 receptor 
specific antibody might need to be carried out in the future.  
In contrast, S1PR1 agonists enhanced platelet activation whereas the S1PR1 antagonist 
inhibited platelet activation. Therefore, it is likely that the S1PR1 is expressed on human 
platelets and that the positive priming effect of S1P is mediated through the S1PR1 receptor 
(Fig. 31). Studies indicate activation of the Gαi/o coupled S1PR1 results in that activation of 
PI3K-Akt, ERK and Rac in various cell types such as ovarian cancer cells152, endothelial 
cells153 and smooth muscle cells154, and can induce cell migration, secretion and proliferation. 
However, further studies on S1PR1 signal transduction in platelets need to be conducted. 
Pre-treatment of platelets with the S1PR4 agonist significantly inhibited PAR1-AP mediated 
aggregation, this finding agrees with Onuma et al85 which found that high concentrations of 
S1P or addition of the S1PR4 agonist strongly inhibited CRP-mediated platelet function. 
Furthermore, aggregation data indicated that inhibition of the S1PR4 significantly enhanced 
platelet aggregation. These findings suggest S1PR4 is expressed on platelets and might play 
a role in negatively regulating platelet function. Intriguingly, CYM50260 did not inhibit but 
slightly increased platelet integrin αIIbβ3 activation. In addition, aggregation data showed for 
the first time, that pre-treatment of platelets with the S1PR5 agonist A971432 can significantly 
reduce platelet responses. It was reported A971432 strongly inhibit forskolin cAMP production 
in S1PR5 overexpressing CHO cells155. In addition, activation of S1PR5 can enhance blood 
brain barrier function and reverse cognitive decline in animal models156. However, the lack of 
a commercially available S1PR5 antagonist means we were unable to determine the effect of 
inhibiting this receptor in regulating platelet. From these data we can deduce that both S1PR4 
and S1PR5 are likely to be expressed on platelets, which is in agreement with platelet 




Activation of S1PR4 and S1PR5 inhibited platelet spreading, suggesting that S1PR4 and 
S1PR5 negatively regulate platelet cytoskeletal dynamics. Several authors have indicated that 
S1PR4 and S1PR5 primarily couple to Gα12/13 subunit over Gαi/o, however, activation of the 
S1PR4 and S1PR5 uniquely results in inhibition of Rho family small GTPase Rac1157, 158. It was 
demonstrated Rac1 plays an important role in regulating platelet lamellipodia formation and 
contributes to aggregate stability16. Recently, Okamoto et al137 have demonstrated the 
inhibitory effects of S1P on CHO cells migration was mediated via activation of a Rac GAP 
(GTPase-activating protein). Activation of Rac-GAP converts Rac to a GDP bound low affinity 
state, which limits plasma membrane ruffling, cell migration and cytoskeletal rearrangement. 
High concentrations of S1P were also found to inhibit PDGF and IGF1 induced Rac activation 
in airway smooth muscle cell159. Therefore, this study suggests that the inhibitory effect of 
high concentrations of S1P are mediated through the activation of S1PR4 and S1PR5 resulting 
in Rac1 inhibition (Fig. 31). In addition, S1PR5 was reported to inhibit ERK signalling pathway, 
which might result in less TxA2 being synthesized and released from platelets160. However, 
the activity of Rac1 and Rac-GAP and signal transduction downstream of these two receptors 
in platelets needs further examination.  
4.6.3 The positive priming effect of S1P on PAR1-induced platelet function is 
mediated via activation of S1PR and PI3K. 
As this project is focused on studying the positive effects of primers, it was important to 
examine the underlying mechanism by which S1P could enhance platelet activation. 
Aggregation data confirmed that S1P alone did not induce platelet aggregation but synergized 
with low concentrations of PAR1-AP to enhance platelet function. The inability of S1P to 
induce aggregation by itself is in line with findings by Ulrych et al107 but contradicts the findings 
of Igarashi et al161. Platelet aggregation induced by subthreshold concentrations of PAR1-AP 
was significantly increased in the presence of 100 nM S1P, this finding is in line with work by 
Urtz et al54. Similar observations were also found by Ruan et al162 where S1P was found to 
significantly potentiate ADP and adrenaline induced platelet aggregation. In contrast, S1P 
only caused small increases when platelets were stimulated with higher concentrations (1.5 - 
2.0 μM) of PAR1-AP, which might be due to the platelets having reached maximal aggregation. 
Furthermore, PAR1-AP mediated integrin αIIbβ3 activation and P-selectin exposure was 
significantly enhanced with pre-incubation of 100 nM S1P. This is consistent with studies on 
sphingosine kinase 2 knock out mice, where a significant decrease in PAR4-AP mediated 
integrin αIIbβ3 activation was rescued by applying exogenous S1P133.  
Immunoblotting experiments were carried out to investigate the downstream signalling of S1P 
in priming platelet function, with the phosphorylation of AktS473, ERK1/2 and VASPS239 
investigated. Immunoblot results demonstrated that S1P alone induced PKB/Akt 
phosphorylation in human platelets. Similar observation were also found in hippocampus 
83 
 
neurons163 and intestinal epithelial cells164 treated with sub-micromolar exogenous S1P. 100 
nM and 300 nM S1P induced the greatest amount of pAktS473 with higher concentrations not 
inducing phosphorylation.  This might be the result of different S1P receptors being activated, 
the S1P binding affinity on S1PR1 and S1PR5 are 8 nM and 64 nM respectively. A possible 
explanation is high concentrations of S1P start to activate the low affinity Gα12/13 coupled 
S1PR4 receptors resulting in less PKB phosphorylation and platelet inhibition. No obvious 
ERK phosphorylation was induced by S1P alone in human platelets, in contrast, studies found 
significant increases in ERK phosphorylation in osteoblasts cell treated with S1P and S1PR1 
overexpressed HeLa cells139, 165. This might because ERK phosphorylation mediated via 
S1PR1 is weak or counteracted by effect of S1P at other S1PRs. In addition, there was a time-
dependent effect of S1P on pAktS473, S1P induced peak phosphorylation within 3 - 5 minutes 
with less phosphorylation of Akt observed at 10 - 30 minutes, suggesting possible receptor 
internalization occurring. It was reported S1P receptors can be rapidly internalized upon 
stimulation with S1P and recycled back to cell membrane after 30 minutes166.  
Additive effects between S1P and PAR1-AP were observed on platelet aggregation, integrin 
activation and signal transduction. PAR1-AP mediated AktS473 and ERK1/2 phosphorylation 
were enhanced in the presence of 100 nM S1P. AktS473 phosphorylation was ablated by the 
addition of the pan-PI3K inhibitor wortmannin, as expected. Similarly, Takeya et al167 found 
that S1P enhanced thrombin induced tissue factor expression and sustain thrombin induced 
activation of ERK. Since S1P enhances PAR1-mediated ERK signalling, theoretically PAR1-
AP mediated TxA2 production could be enhanced in the presence of S1P. Furthermore, 
Cheng et al168 found S1P induce COX-2 expression and upregulate PGE2 release in human 
granulosa cells. However, measurements of TxB2 production found only a small non-
significant increase in PAR1-AP mediated TxA2 synthesis induced by S1P. In this study, the 
TxB2 samples were prepared under non-stirring condition, therefore the effect of S1P under 
stirring conditions should be investigated in future studies. Furthermore, as sphingolipids are 
extremely hydrophobic, under non-stirring condition S1P may form a monolayer on the 
aqueous surface instead of interacting with platelets130.  
Lastly, immunoblotting experiment indicate S1P alone did not induce phosphorylation of 
VASPS239 but did reduce PGE1 mediated VASPS239 phosphorylation. It was reported S1P pre-
treatment reduced forskolin induced cAMP production and resulted in a rapid phosphorylation 
of Akt in mouse embryonic fibroblasts, these observations were abolished by pertussis toxin 
(PTX)169, suggest Gαi coupling of the S1P receptors. Another study also found PTX treatment 
completely abolished S1P or dihydro-S1P induced cell proliferation in mesangial cells. My 
data is in consistent with these studies suggest S1P signalling via Gαi/o coupled receptors.  
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4.6.4 Sphingosine kinases play a role in regulating platelet function 
Platelets lack SPP and SPL but exhibit constitutive activity of sphingosine kinases (Sphk). 
Inhibition of sphingosine kinase significantly reduced PAR1-AP mediate platelet aggregation. 
The competitive sphingosine kinase-1/2 inhibitor DMS significantly inhibited PAR1-AP 
induced platelet aggregation in a concentration dependent manner. This is consistent with 
experiments showing DMS inhibited platelet aggregation170, and concentration dependently 
inhibited de novo S1P synthesis in human platelet. Similarly, pre-treatment with the selective 
SphK1 inhibitor PF543 hydrochloride (IC50 = 2nM, Ki = 3.6 nM) reduced platelet aggregation, 
but the inhibitory effect induced by PF543 hydrochloride was much less than with the same 
concentration of DMS. Although the DMS has a much higher IC50 of 500 nM and Ki of 3 μM. 
These results suggest SphK2 is the major sphingosine kinase in regulate platelet function, 
which is in agreement with SphK2 knock out mice studies showing deficiency in platelet 
aggregation and thrombus formation resulted prolonged tail bleeding time54. However, human 
platelet transcriptome data indicate that SphK1 has a 48-fold higher expression level than 
SphK2.  Due to there being no commercially available selective SphK2 inhibitors when this 
study was conducted, the effect of selectively inhibiting SphK2 in human platelets remains 
unclear. Recently, a novel selective SphK2 inhibitor SLM 6031434 hydrochloride (Ki = 0.4 μM) 
has become available on the market, which could be used to test the effect of inhibiting 
platelet SphK2 in future experiments.  
Inhibition of sphingosine kinases also reduced platelet spreading, the concentration of DMS 
used (1 μM) was not capable of inhibiting PKC171. The average platelet area was reduced, 
and fewer platelets were adhered. Suggesting sphingosine kinases are involved in regulating 
platelet morphology change. A recent study suggests the de novo synthesized S1P is 
transported through the phospholipid bilayer membrane, rapidly activate the S1P receptors 
expressed on the cell surface110. In line with aggregation data and platelet spreading results, 
we suggest sphingosine kinases can regulate platelet function, possibly via control the de 
novo synthesized S1P and subsequent autocrine signalling via the S1P receptors expressed.    
Interestingly, a much less selective SphK2 inhibitor ABC294640 (Ki = 9.8 μM) is in phase I/II 
clinical trial under the brand name Yeliva® (RedHill Biopharma) for the treatment of 
cholangiocarcinoma, multiple myeloma and solid tumor172,173. Ongoing clinical trials data 
suggest the plasma S1P levels can be used as a novel biomarker for monitor cancer treatment. 
Orally administrated ABC294640 resulted in a rapid decrease of plasma S1P levels in patients 





Chapter 5. General discussion 
5.1 Summary of the study 
Platelets play a central role in maintaining haemostasis but also contribute to the development 
of thrombotic disorders and atherosclerosis. Cardiovascular disease is the current leading 
cause of death worldwide, diseases such as diabetes, obesity and chronic inflammation 
contribute to the pathogenesis of thrombotic events176. Studies have found that elevated 
levels of circulating platelet primers can enhance platelet reactivity increasing the risk of 
thrombosis. The underlying mechanism of existing platelet primers such as IGF-1, TPO and 
PGE2 has been well established, however, there is overwhelming evidence to suggest that 
other primers of platelet function exist. 
In Chapter 3 of this thesis, a list of potential platelet primers was selected based on the 
corresponding receptor signalling mechanism, receptor transcriptome expression level and 
literature studies. Aggregation data confirmed that IGF-1, TPO and sulprostone enhance 
platelet function, some novel platelet primers including CCL17, CCL22, S1P, IL-34, and 
PDGF-AA were identified. After thoroughly evaluating the priming effect and comparing the 
novelty of these primers in the literature, S1P was selected as the “novel platelet primer” for 
further study. In Chapter 4 of this thesis, the effect of S1P on platelet function was examined 
in detail. Data indicate that S1P exhibit a concentration dependent biphasic effect on human 
platelet function; the positive priming effect might be mediated via S1PR1 activation resulting 
in the activation of PI3K and the negative priming effect mediated via S1PR4, 5 activation 
resulting in the inhibition of Rac small GTPase. Furthermore, this study also demonstrates 
that sphingosine kinases play a role in controlling platelet function. 
5.2 Clinical implications and the bigger picture of S1P 
As previously described, elevated S1P levels have been found to be associated with many 
diseases including ovarian cancer, atherosclerosis and diabetes. It was reported that S1P 
can synergize with thrombin to promote the blood clotting process and play an important role 
in regulating endothelial cell response128. This study found S1P can both enhance and inhibit 
PAR1-AP platelet function. A proposed mechanism of in vivo S1P priming platelet function is 
shown in Fig. 32. Diseases such as diabetes result in increased level of oxidation and 
glycation on ApoM/ApoA1 associated HDL, which cause defected HDL function. This disease 
induced HDL modification impairs the HDL-S1P interaction, resulting in more S1P being 
released into the circulation 177 . Elevated bioactive S1P can bind to the S1P receptors 
expressed on platelets or endothelial cells to amplify downstream signalling through S1P 
receptors, resulting in increased platelet function and elevated endothelial responses. It was 
reported that exogenous S1P can induce S1PR1 receptor expression, which also contributes 




Figure 32. Schematic diagram showing (A) Proposed mechanisms of disease induced HDL 
dysfunction resulted S1P priming of platelet and endothelial cell response. (B) A potential 
vasoprotective effect mediated by the concentration dependent biphasic effects of S1P. Figures 
adapted from Sattler et al179 and Alila Medical Media180 
Interestingly, many studies on endothelial cells and cardiomyocytes also found S1P exhibits 
both vasoprotective and cardioprotective effects. Exogenous S1P application was found to 
enhance the viability of cardiomyocytes under hypoxia condition, this protective effect is 
primarily mediated via activation of S1PR1, 2, 3 receptors expressed on the cells181. A similar 
study on endothelial cells found low level thrombin induced vasoprotective effects were 
abolished in the presence of S1PR1 siRNA or pertussis toxin (PTX), which imply there is a 
synergistic protective effect between PAR1 and S1PR1 receptors182. Downstream signalling 
of S1P receptors on these cells results in increased cell proliferation, promotes PI3K-Akt 
mediated survival signalling and increases PKC mediated nitric oxide synthase activation183. 
A proposed mechanism of S1P vasoprotective effect is shown in Fig. 32B. Injury to blood 
vessels causes endothelial cells and red blood cells to release S1P. Initial increases of 
bioactive S1P primes the circulating platelet function, promoting blood clotting and platelet 
aggregation at the site of injury. Subsequently, activated platelets release S1P contained in 
their granules and initiate de novo S1P synthesis, resulting in an increase in the local 
concentration of S1P. High local concentrations of S1P will induce inhibitory effects on platelet 
function, limiting thrombus growth. Furthermore, local S1P also activates S1P receptors 
expressed on endothelial cells to promote barrier integrity, initiate cell survival and 
proliferation process. By limiting the size and rate of thrombus growth and promote cell survive 
prose, S1P can induce protective effects on cardiomyocytes in a similar way. It was reported 
that low dosage sphingosine kinase inhibitor DMS can provide cardioprotective effects184. 
Although this model is hypothesized based on literature reports and data obtained, future 
studies on S1P protective effect might be conducted and examined in detail.  
In the S1P research field, several drugs have been developed or in the clinic trails. Targeting 
S1PR1 on lymphocytes exhibit immunomodulating effects. Fingolimod is the first S1P receptor 
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modulator developed for treating multiple sclerosis, it can act as a functional antagonist on 
S1PR1 cause receptor degradation and inhibit lymphocytes migration185. Novel S1P related 
immunomodulators can cat as dual agonist on both S1PR1 and S1PR5, which Siponimod and 
Ozanimod are in phase III clinical trials for treating multiple sclerosis and Crohn’s disease186. 
Furthermore, S1PR1 agonist SEW2871 have been shown to reduce ischemic injury and 
exhibit cardioprotective effects in myocardial ischemia mice model 187 . Moreover, it was 
reported that antagonizing S1PR2 using JTE-013 reduce vascular permeability and promote 
endothelial function in mouse stroke model study. The biphasic effect of S1P on platelets 
might lead to identification of novel antiplatelet targets, for instance, targeting the sphingosine 
kinase or S1PR4 and S1PR5 receptors188. Recently, it was reported that Fingolimod treatment 
reduce leukocytes recruitment and inhibit endothelial activation, which might reduce local 
platelet-leukocyte or platelet-endothelial cell interactions189. 
5.3 Future work and conclusion 
There are genetic variations between individual platelet donors which might affect the results 
obtained, since some experiments only have been conducted for limited times, more repeat 
experiments need to be performed. FACS assay using annexin V conjugates can be 
conducted to determine whether the inhibitory effects of high concentrations S1P were 
cytotoxic effects. The S1P receptor subtypes expression profile on human platelets might 
need to be confirmed on immunoblotting with receptor specific antibodies. Moreover, studies 
have shown the synthesis and release of S1P from activated platelets is also regulated by 
PKC and TxA2. Therefore, future investigation is needed to examine the effect of aspirin or 
indomethacin treatment on S1P priming. Future experiments are needed to quantify PAR1-
AP induced de novo S1P synthesis in human platelets using S1P ELISA kit, and the S1P 
release from platelets also could examined by using ABBC4 inhibitor. Furthermore, S1P 
receptor gene knockout mice model could be developed, in particular, S1PR4 knock out mice 
might be designed to study the regulatory effect of this receptor on platelet function. Moreover, 
epidemiological studies could be carried out to exam correlation between S1P level and 
cardiovascular events in patients with diabetes, obesity or chronic inflammation.  
There has been limited research conducted on the effect of S1P on human platelet function, 
while many controversies exist in the literatures. In conclusion, this study has identified S1P 
as a novel platelet primer and demonstrated the underlying mechanism by which S1P affect 
PAR1 mediated platelet function in a concentration dependent biphasic manner. These 
findings may contribute to identify other primers and understand their mechanisms in 
thrombotic disorders. The biphasic effect of S1P might have clinical importance in developing 
novel drugs to diversely modulate platelet function. Since targeting S1P receptors also have 
shown immunomodulating effects, disrupt the platelet-leukocyte interactions via S1P 
receptors might be a novel approach in treatment of thrombosis and chronic inflammation.  
88 
 
Chapter 6. References 
1. Coller, Barry S. "Historical Perspective and Future Directions in Platelet Research." Journal of 
thrombosis and haemostasis : 9, no. Suppl 1 (2011): 374-95. 
2. Rauch, U., J. I. Osende, V. Fuster, J. J. Badimon, Z. Fayad, and J. H. Chesebro. "Thrombus 
Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences." Annals of Internal 
Medicine 134, no. 3 (2001): 224-38. 
3. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular 
Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology. 2017;70(1):1-
25. 
4 . Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. 
2004;117(16):3415-3425. 
5. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in 
patients with cardiovascular disease. The American Journal of Cardiology. 2001;88(3):230-235. 
6. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: a potential target for 
antiplatelet therapy. Trends in Pharmacological Sciences. 2008;29(7):352-360. 
7. Blair TA, Moore SF, Hers I. Circulating primers enhance platelet function and induce resistance to 
antiplatelet therapy. Journal of Thrombosis and Haemostasis. 2015;13(8):1479-1493. 
8. Baaten CCFMJ, ten Cate H, van der Meijden PEJ, Heemskerk JWM. Platelet populations and 
priming in haematological diseases. Blood Reviews. 2017;31(6):389 399. 
9. Fogelson AL, Neeves KB. Fluid Mechanics of Blood Clot Formation. 2015;47(1):377-403. 
10 . Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovascular 
Disorders.2015;15:130. 
11. Brooks MB, Catalfamo JL. Von Willebrand disease Schalm’s Veterinary Hematology. 6th ed. 2010 
Ames: Wiley-Blackwell; pp. 612–618. 
 
12. Rivera J, Lozano ML, Navarro-Núñez L, Vicente V. Platelet receptors and signaling in the dynamics 
of thrombus formation. Haematologica. 2009;94(5):700-711. 
13. Badimon L, Padró T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart 
disease. European Heart Journal Acute Cardiovascular Care. 2012;1(1):60-74. 
14. Goggs R, Williams Christopher M, Mellor H, Poole Alastair W. Platelet Rho GTPases–a focus on 
novel players, roles and relationships. Biochemical Journal. 2015;466(Pt 3):431-442. 
15. McCarty OJT, Larson MK, Auger JM, et al. Rac1 Is Essential for Platelet Lamellipodia Formation 
and Aggregate Stability under Flow[unk]. The Journal of biological chemistry. 2005;280(47):39474-
39484. 
16. Aslan JE, McCarty OJT. Rho GTPases in Platelet Function. Journal of thrombosis and haemostasis : 
JTH. 2013;11(1):35-46 
17. Varga‐szabo, d., braun, a. and nieswandt, b. (2009), Calcium signalling in platelets. Journal of 
thrombosis and haemostasis, 7: 1057-1066.  
18. Watson, s. p., auger, j. m., mccarty, o. j. and pearce, a. c. (2005), GPVI and integrin αiibβ3 signaling 
in platelets. Journal of thrombosis and haemostasis, 3: 1752-1762. 
19. Blair P, Flaumenhaft R. Platelet α–granules: Basic biology and clinical correlates. Blood reviews. 
2009;23(4):177-189. 
20. King SM, McNamee RA, Houng AK, Patel R, Brands M, Reed GL. Platelet dense granule secretion 







21. Lopez-Vilchez I, Diaz-Ricart M, White JG, Escolar G, Galan AM. Serotonin enhances platelet 
procoagulant properties and their activation induced during platelet tissue factor uptake. 
Cardiovascular Research. 2009;84(2):309-316. 
22. Ambrosio AL, Boyle JA, Di Pietro SM. Mechanism of platelet dense granule biogenesis: study of 
cargo transport and function of Rab32 and Rab38 in a model system. Blood. 2012;120(19):4072-4081. 
23. Kaushansky K, Williams WJ. Williams Hematology. McGraw-Hill Medical; 2010. 
24 Fontana P, Zufferey A, Daali Y, Reny JL. Antiplatelet Therapy: Targeting the TxA2 Pathway. Journal 
of Cardiovascular Translational Research. 2014;7(1):29-38. Smyth EM. Thromboxane and the 
thromboxane receptor in cardiovascular disease. Clinical lipidology. 2010;5(2):209-219. 
25 . Smyth EM. Thromboxane and the thromboxane receptor in cardiovascular disease. Clinical 
lipidology. 2010;5(2):209-219. 
26. Rivera J, Lozano ML, Navarro-Núñez L, Vicente V. Platelet receptors and signaling in the dynamics 
of thrombus formation. Haematologica. 2009;94(5):700. 
27. Rosing J, van Rijn JL, Bevers EM, van Dieijen G, Comfurius P, Zwaal RF. The role of activated 
human platelets in prothrombin and factor X activation. Blood. 1985;65(2):319. 
28 Mills JL, DerSimonian R, Raymond E, et al. Prostacyclin and thromboxane changes predating 
clinical onset of preeclampsia: A multicentre prospective study. JAMA. 1999;282(4):356-362. 
29. Bennett JS, Berger BW, Billings PC. The structure and function of platelet integrins. Journal of 
Thrombosis and Haemostasis. 2009;7(s1):200-205. 
30. Stalker TJ, Welsh JD, Tomaiuolo M, et al. A systems approach to hemostasis: 3. Thrombus 
consolidation regulates intrathrombus solute transport and local thrombin activity. Blood. 
2014;124(11):1824-1831. 
31 . Lisman T, Weeterings C, G de Groot P. Platelet aggregation: involvement of thrombin and 
fibrin(ogen). Vol 102005. 
32. van Werkum JW, Gerritsen WBM, Kelder JC, et al. Inhibition of platelet function by abciximab or 
high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. Netherlands 
Heart Journal. 2007;15(11):375-381 
33. Panova-Noeva M, Marchetti M, Russo L, et al. ADP-induced platelet aggregation and thrombin 
generation are increased in Essential Thrombocythemia and Polycythemia Vera. Thrombosis 
Research. 2013;132(1):88-93. 
34. Gear ARL, Suttitanamongkol S, Viisoreanu D, Polanowska-Grabowska RK, Raha S, Camerini D. 
Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to 
stimulate platelet function. Blood. 2001;97(4):937 
35. Stefanini L, Paul DS, Robledo RF, et al. RASA3 is a critical inhibitor of RAP1-dependent platelet 
activation. The Journal of Clinical Investigation. 2015;125(4):1419-1432. 
36. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long Term Use of Aspirin and the Risk of 
Gastrointestinal Bleeding. The American journal of medicine. 2011;124(5):426-433. 
37. IUPHAR/BPS guide to pharmacology. [Online] http://www.guidetopharmacology.org [accessed 
15/06/2018] 
38. Abcam. 2014 [online]https://www.abcam.com/11-dehydro-txb2-elisa-kit-ab133054.html [accessed 
23/07/2018] 
39. DeFilippis AP, Rai SN, Cambon A, et al. Fatty acids and TxA(2) generation, in the absence of 
platelet-COX-1 activity. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2014;24(4):428-
433. 
40. Harrison P, Lordkipanidzé M. Chapter 26 - Clinical Tests of Platelet Function. In: Michelson AD, ed. 
Platelets (Third Edition). Academic Press; 2013:519-545. 
41. Lupia E, Bosco O, Mariano F, et al. Elevated thrombopoietin in plasma of burned patients without 






42 . Blair, T., & University of Bristol, degree granting institution. Investigations into the Role of 
Phosphoinositide 3-kinase (P13K) in Platelet Priming and Antiplatelet Resistance. 2016 
43 . Bates DO. Vascular Endothelial Growth Factors and vascular permeability. Cardiovascular 
research. 2010;87(2):262-271. 
44. Dorsam RT, Kunapuli SP. Central role of the P2Y(12) receptor in platelet activation. Journal of 
Clinical Investigation. 2004;113(3):340-345. 
45. Siehler S. Regulation of RhoGEF proteins by G(12/13)-coupled receptors. British Journal of 
Pharmacology. 2009;158(1):41-49 
46. Egan KM, Lawson JA, Fries S, et al. COX-2-Derived Prostacyclin Confers Atheroprotection on 
Female Mice. Science. 2004;306(5703):1954. 
47. Clancy L, Freedman JE. The role of circulating platelet transcripts. Journal of Thrombosis and 
Haemostasis. 2015;13(S1):S33-S39. 
48. Assou S, Boumela I, Haouzi D, et al. Dynamic changes in gene expression during human early 
embryo development: from fundamental aspects to clinical applications. Human Reproduction Update. 
2010;17(2):272-290. 
49. Rowley JW, Oler AJ, Tolley ND, et al. Genome-wide RNA-seq analysis of human and mouse 
platelet transcriptomes. Blood. 2011;118(14):e101-e111. 
50. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based 
approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of 
Sciences of the United States of America. 2005;102(43):15545-15550. 
51. Imai, T., Chantry, D., Raport, C.J., Wood, C.L., Nishimura, M., Godiska, R., Yoshie, O., & Gray, 
P.W. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. The 
Journal of biological chemistry, 1998; 273 3, 1764-8. 
52. Friedman EA, Ogletree ML, Haddad EV, Boutaud O. Understanding the role of prostaglandin E(2) 
in regulating human platelet activity in health and disease. Thrombosis research. 2015;136(3):493-503. 
53 . Pasterk L, Philipose S, Eller K, Marsche G, Heinemann A, Schuligoi R. The EP3 Agonist 
Sulprostone Enhances Platelet Adhesion But Not Thrombus Formation Under Flow Conditions. 
Pharmacology. 2015;96(3-4):137-143. 
54. Urtz N, Gaertner F, von Bruehl ML, et al. Sphingosine 1-Phosphate Produced by Sphingosine 
Kinase 2 Intrinsically Controls Platelet Aggregation In Vitro and In Vivo. Circ Res. 2015;117(4):376-
387. 
55. Johns DG, Behm DJ, Walker DJ, et al. The novel endocannabinoid receptor GPR55 is activated 
by atypical cannabinoids but does not mediate their vasodilator effects. British Journal of Pharmacology. 
2007;152(5):825-831. 
56. Li Z, Jin D, Wu Y, et al. Increased Serum Interleukin-34 in Patients with Coronary Artery Disease. 
Journal of International Medical Research. 2012;40(5):1866-1870. 
57. Selheim F, Holmsen H, Vassbotn FS. Platelet-Derived Growth Factor Inhibits Platelet Activation in 
Heparinized Whole Blood. Thrombosis Research. 1999;95(4):185-196. 
58. Vassbotn FS, Havnen OK, Heldin CH, Holmsen H. Negative feedback regulation of human platelets 
via autocrine activation of the platelet-derived growth factor alpha-receptor. 1994;269(19):13874-
13879. 
59. Zhang S, Yuan J, Yu M, et al. IL-17A Facilitates Platelet Function through the ERK2 Signaling 
Pathway in Patients with Acute Coronary Syndrome. PLOS ONE. 2012;7(7):e40641. 
60. Leung TF, Wong CK, Lam CWK, et al. Plasma TARC concentration may be a useful marker for 
asthmatic exacerbation in children. European Respiratory Journal. 2003;21(4):616. 
61. Fujisawa T, Fujisawa R, Kato Y, et al. Presence of high contents of thymus and activation-regulated 
chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and 






62. Leung TF, Wong GWK, Ko FWS, Lam CWK, Fok TF. Increased macrophage-derived chemokine 
in exhaled breath condensate and plasma from children with asthma. Clinical & Experimental Allergy. 
2004;34(5):786-791. 
63. Wertel I, Surówka J, Polak G, et al. Macrophage-derived chemokine CCL22 and regulatory T cells 
in ovarian cancer patients. Tumour Biology. 2015;36(6):4811-4817. 
64. Kuo H-C, Wang C-L, Yang KD, et al. Plasma Prostaglandin E2 Levels Correlated with the 
Prevention of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions Fo.rmation via 
CD40L in Kawasaki Disease. PLOS ONE. 2016;11(8):e0161265. 
65 Kowalski GM, Carey AL, Selathurai A, Kingwell BA, Bruce CR. Plasma Sphingosine-1-Phosphate 
Is Elevated in Obesity. PLOS ONE. 2013;8(9):e72449. 
66. Huestis MA. Human Cannabinoid Pharmacokinetics. Chemistry & biodiversity. 2007;4(8):1770-
1804. 
67. Zhang L, Curhan GC, Forman JP. Plasma Insulin-Like Growth Factor -1 Level and Risk of Incident 
Hypertension in Non-Diabetic Women. Journal of hypertension. 2011;29(2):229-235. 
68 . Peyrat JP, Louchez MM, Lefebvre J, et al. Plasma insulin-like growth factor-1 (IGF-1) 
concentrations in human breast cancer. European Journal of Cancer. 1993;29(4):492-497. 
69. Chang E-J, Lee SK, Song YS, et al. IL-34 Is Associated with Obesity, Chronic Inflammation, and 
Insulin Resistance. The Journal of Clinical Endocrinology & Metabolism. 2014;99(7):E1263-E1271. 
70. Hwang S-J, Choi B, Kang S-S, et al. Interleukin-34 produced by human fibroblast-like synovial cells 
in rheumatoid arthritis supports osteoclastogenesis. Arthritis Research & Therapy. 2012;14(1):R14. 
71. Saitoh T, Kishida H, Tsukada Y, et al. Clinical significance of increased plasma concentration of 
macrophage colony–stimulating factor in patients with angina pectoris. Journal of the American College 
of Cardiology. 2000;35(3):655-665. 
72. Ramirez GA, Blasi M, Sciorati C, Rovere-Querini P, Manfredi AA. Plasma levels of M-CSF are 
increased in ANCA-associated vasculitides with active nephritis. Results in Immunology. 2015;5:33-36. 
73. Wallace JMW, Freeburn JC, Gilmore WS, et al. The Assessment of Platelet Derived Growth Factor 
Concentration in Post Myocardial Infarction and Stable Angina Patients. Annals of Clinical Biochemistry. 
1998;35(2):236-241 
74. Bertagnolli TV, Rangel Machado MS, Rangel Machado JS, Cavalli RC, Duarte G. Evaluation of 
plasma concentration of the platelet-derived growth factor (PDGF AA) in the prediction of preeclampsia: 
Risk factors, prediction of preeclampsia. Pregnancy Hypertension: An International Journal of Women's 
Cardiovascular Health. 2016;6(3):196-197. 
75. Cenni E, Savarino L, Antonioli D, Pellacani A, Giunti A, Baldini N. Plasma levels of platelet-derived 
growth factor BB and transforming growth factor in patients with failed hip prostheses. Acta 
Orthopaedica. 2005;76(1):61-66. 
76. Rossi E, Casali B, Regolisti G, et al. Increased Plasma Levels of Platelet-Derived Growth Factor 
(PDGF-BB + PDGF-AB) in Patients with Never-Treated Mild Essential Hypertension. American Journal 
of Hypertension. 1998;11(10):1239-1243. 
77. Dhaouadi T, Chahbi M, Haouami Y, et al. IL-17A, IL-17RC polymorphisms and IL17 plasma levels 
in Tunisian patients with rheumatoid arthritis. PLOS ONE. 2018;13(3):e0194883. 
78. Shukla A, Grove S, Barbero S, et al. Abstract 2241: Serum and plasma IL-17A concentrations in 
lung cancer patients and controls. Cancer Research. 2016;76(14 Supplement):2241. 
79. Tamura, Ogata, Luo, et al. Plasma thrombopoietin (TPO) levels and expression of TPO receptor 
on platelets in patients with myelodysplastic syndromes. British Journal of Haematology. 
2002;103(3):778-784. 
80 . Hou, Andersson, Stockelberg, Mellqvist, Ridell, Wadenvik. Plasma thrombopoietin levels in 
thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. British 





81. Shenkman B, Brill A, Brill G, Lider O, Savion N, Varon D. Differential response of platelets to 
chemokines: RANTES non-competitively inhibits stimulatory effect of SDF-1α. Journal of Thrombosis 
and Haemostasis. 2004;2(1):154-160. 
82. Abi-Younes S, Si-Tahar M, D. Luster A. The CC chemokines MDC and TARC induce platelet 
activation via CCR4. Vol 1012001. 
83. Yu X, Marshall MJE, Cragg MS, Crispin M. Improving Antibody-Based Cancer Therapeutics 
Through Glycan Engineering. BioDrugs. 2017;31(3):151-166. 
84. Markovič T, Jakopin Ž, Dolenc MS, Mlinarič-Raščan I. Structural features of subtype-selective EP 
receptor modulators. Drug Discovery Today. 2017;22(1):57-71. 
85. Onuma T, Tanabe K, Kito Y, et al. Sphingosine 1-phosphate (S1P) suppresses the collagen-
induced activation of human platelets via S1P4 receptor. Thrombosis Research. 2017;156:91-100. 
86. Chihara T, Suzu S, Hassan R, et al. IL-34 and M-CSF share the receptor Fms but are not identical 
in biological activity and signal activation. Cell Death And Differentiation. 2010;17:1917. 
87. Eda H, Zhang J, Keith RH, Michener M, Beidler DR, Monahan JB. Macrophage-colony stimulating 
factor and interleukin-34 induce chemokines in human whole blood. Cytokine. 2010;52(3):215-220. 
88 . Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in 
atherosclerosis: studies of osteopetrotic mice. The American Journal of Pathology. 1997;150(5):1687-
1699. 
89. Suzuki M, Ohwada M, Aida I, Sato I, Tamada T. Macrophage Colony-Stimulating Factor Enhances 
Platelet Recovery Following Cisplatin/Carboplatin Chemotherapy in Ovarian Cancer. Gynecologic 
Oncology. 1994;54(1):23-26. 
90. Lin X, Takahashi K, Liu Y, Derrien A, Zamora PO. A synthetic, bioactive PDGF mimetic with binding 
to both α-PDGF and β-PDGF receptors. Growth Factors. 2007;25(2):87-93. 
91. Valeri CR, Saleem B, Ragno G. Release of platelet-derived growth factors and proliferation of 
fibroblasts in the releasates from platelets stored in the liquid state at 22°C after stimulation with 
agonists. Transfusion. 2005;46(2):225-229. 
92. Ye JY, Chan GCF, Qiao L, et al. Platelet-derived growth factor enhances platelet recovery in a 
murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its 
receptors and the PI3-k/Akt pathway. Haematologica. 2010;95(10):1745-1753. 
93. Szabo S, Vincze Á. Growth factors in ulcer healing: Lessons from recent studies. Journal of 
Physiology-Paris. 2000;94(2):77-81. 
94. Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA. The procoagulatory effects of delta-9-
tetrahydrocannabinol in human platelets. Anesthesia and analgesia. 2004;99(4):1127-1130, table of 
contents. 
95. Lauckner JE, Jensen JB, Chen H-Y, Lu H-C, Hille B, Mackie K. GPR55 is a cannabinoid receptor 
that increases intracellular calcium and inhibits M current. Proceedings of the National Academy of 
Sciences of the United States of America. 2008;105(7):2699-2704. 
96. Kargl J, Brown AJ, Andersen L, et al. A Selective Antagonist Reveals a Potential Role of G Protein–
Coupled Receptor 55 in Platelet and Endothelial Cell Function. Journal of Pharmacology and 
Experimental Therapeutics. 2013;346(1):54. 
97. Oliveira D, Heide E, Brandt C, Rego M, Pitta M, Pitta I. Interleukin 17A in Patients With Stable 
Coronary Artery Disease: Are There Differences According to Gender? Cardiology Research. 
2014;5(6):171-175. 
98. Yatomi Y, Ozaki Y, Ohmori T, Igarashi Y. Sphingosine 1-phosphate: synthesis and release. 
Prostaglandins & Other Lipid Mediators. 2001;64(1):107-122. 
99. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in 
immunity. Nature reviews Immunology. 2008;8(10):753-763. 
100. Levkau B. HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic 






101. Moritz E, Wegner D, Groß S, et al. Reference intervals for serum sphingosine-1-phosphate in the 
population-based Study of Health in Pomerania. Clinica Chimica Acta. 2017;468:25-31. 
102 . Xiong Y, Hla T. S1P Control of Endothelial Integrity. Current topics in microbiology and 
immunology. 2014;378:85-105. 
103. Hammad SM, Al Gadban MM, Semler AJ, Klein RL. Sphingosine 1-Phosphate Distribution in 
Human Plasma: Associations with Lipid Profiles J Journal of Lipids. 2012;2012:8. 
104. Hla T, Venkataraman K, Michaud J. The vascular S1P gradient—Cellular sources and biological 
significance. Biochimica et biophysica acta. 2008;1781(9):477-482. 
105. Książek M, Chacińska M, Chabowski A, Baranowski M. Sources, metabolism, and regulation of 
circulating sphingosine-1-phosphate. Journal of Lipid Research. 2015;56(7):1271-1281. 
106. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-Phosphate Receptor 
Signaling. Annual Review of Biochemistry. 2009;78(1):743-768. 
107. Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P) Physiology and the effects of S1P receptor 
modulation. Vol 762011. 
108. Sanford M. Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis. Drugs. 
2014;74(12):1411-1433. 
109. Nagahashi M, Yamada A, Katsuta E, et al. Targeting the SphK1/S1P/S1PR1 Axis That Links 
Obesity, Chronic Inflammation, and Breast Cancer Metastasis. Cancer Research. 2018;78(7):1713. 
110. Chae S-S, Paik J-H, Furneaux H, Hla T. Requirement for sphingosine 1–phosphate receptor-1 in 
tumor angiogenesis demonstrated by in vivo RNA interference. Journal of Clinical Investigation. 
2004;114(8):1082-1089. 
111 . Isphingo. S1P/S1PR signalling. 2011 [Online] 
https://www.flickr.com/photos/61869380@N05/6194782978 [Accessed on 14/08/2018] 
112. Wang D, Zhao Z, Caperell-Grant A, et al. S1P differentially regulates migration of human ovarian 
cancer and human ovarian surface epithelial cells. Molecular cancer therapeutics. 2008;7(7):1993-
2002. 
113. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signalling and its role 
in disesases. Trends in Cell Biology. 2012;22(1):50-60 
114 . Böhm A, Flößer A, Ermler S, et al. Factor-Xa-induced mitogenesis and migration require 
sphingosine kinase activity and S1P formation in human vascular smooth muscle cells. Cardiovascular 
Research. 2013;99(3):505-513. 
115. Meissner A, Miro F, Jiménez-Altayó F, Jurado A, Vila E, Planas AM. Sphingosine-1-phosphate 
signalling—a key player in the pathogenesis of Angiotensin II-induced hypertension. Cardiovascular 
Research. 2017;113(2):123-133. 
116. Ikeda M, Kihara A, Igarashi Y. Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-
resident, integral membrane protein with the pyridoxal 5′-phosphate binding domain exposed to the 
cytosol. Biochemical and Biophysical Research Communications. 2004;325(1):338-343. 
117. Weth D, Benetti C, Rauch C, et al. Activated platelets release sphingosine 1-phosphate and 
induce hypersensitivity to noxious heat stimuli in vivo. Frontiers in Neuroscience. 2015;9:140. 
118. Ulrych T, BÖHm A, Polzin A, et al. Release of sphingosine-1-phosphate from human platelets is 
dependent on thromboxane formation. Journal of Thrombosis and Haemostasis. 2011;9(4):790-798. 
119 . Yatomi Y, Igarashi Y, Yang L, et al. Sphingosine 1-Phosphate, a Bioactive Sphingolipid 
Abundantly Stored in Platelets, Is a Normal Constituent of Human Plasma and Serum. The Journal of 
Biochemistry. 1997;121(5):969-973. 
120. Münzer P, Schmid E, Walker B, et al. Sphingosine kinase 1 (Sphk1) negatively regulates platelet 






121 . Jonnalagadda D, Sunkara M, Morris AJ, Whiteheart SW. Granule-Mediated Release of 
Sphingosine-1-Phosphate by Activated Platelets*. Biochimica et biophysica acta. 2014;1841(11):1581-
1589. 
122. Marcantoni E, Allen N, Cambria MR, et al. Platelet Transcriptome Profiling in HIV and ATP-
Binding Cassette Subfamily C Member 4 (ABCC4) as a Mediator of Platelet Activity. JACC: Basic to 
Translational Science. 2018;3(1):9-22 
123. Kobayashi N, Nishi T, Hirata T, et al. Sphingosine 1-phosphate is released from the cytosol of rat 
platelets in a carrier-mediated manner. Journal of Lipid Research. 2006;47(3):614-621. 
124. Hla T, Galvani S, Rafii S, Nachman R. S1P and the birth of platelets. The Journal of Experimental 
Medicine. 2012;209(12):2137. 
125 . Massberg S. The Role of Sphingosine-1-Phosphate (S1P) in Thrombopoiesis. Blood. 
2014;124(21):SCI-54. 
126. Golfier S, Kondo S, Schulze T, et al. Shaping of terminal megakaryocyte differentiation and 
proplatelet development by sphingosine-1-phosphate receptor S1P4. The FASEB Journal. 
2010;24(12):4701-4710. 
127. Zhang L, Orban M, Lorenz M, et al. A novel role of sphingosine 1-phosphate receptor S1PR1 in 
mouse thrombopoiesis. The Journal of Experimental Medicine. 2012;209(12):2165-2181. 
128. Yamamura S, Yatomi Y, , Ruan F, Igarashi Y. Sphingosine 1-Phosphate Induces Platelet 
Activation through an Extracellular Action and Shares a Platelet Surface Receptor with 
Lysophosphatidic Acid. Journal of Biological Chemistry. 1997;272(8):5291-5297. 
129. Randriamboavonjy V, Badenhoop K, Schmidt H, Geisslinger G, Fisslthaler B, Fleming I. The S1P2 
receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated 
in type 2 diabetes. Basic Research in Cardiology. 2009;104(3):333-340 
130. García-Pacios M, Collado MI, Busto JV, et al. Sphingosine-1-Phosphate as an Amphipathic 
Metabolite: Its Properties in Aqueous and Membrane Environments. Biophysical Journal. 
2009;97(5):1398-1407. 
131. Cohen JA, Barkhof F, Comi G, et al. Oral Fingolimod or Intramuscular Interferon for Relapsing 
Multiple Sclerosis. New England Journal of Medicine. 2010;362(5):402-415. 
132. Ghosh TK, Bian J, Gill DL. Sphingosine 1-phosphate generated in the endoplasmic reticulum 
membrane activates release of stored calcium. Journal of Biological Chemistry. 1994;269(36):22628-
22635. 
133. Gazit SL, Mariko B, Therond P, et al. Platelet and Erythrocyte Sources of S1P Are Redundant for 
Vascular Development and Homeostasis, but both Rendered Essential After Plasma S1P Depletion in 
Anaphylactic Shock. Circulation research. 2016;119(8):e110-e126 
134 . Takuwa N, Du W, Kaneko E, Okamoto Y, Yoshioka K, Takuwa Y. Tumor-suppressive 
sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate 
receptor-1 and sphingosine kinase 1 — Jekyll Hidden behind Hyde. American Journal of Cancer 
Research. 2011;1(4):460-481 
135. Cencetti F, Bernacchioni C, Tonelli F, Roberts E, Donati C, Bruni P. TGFβ1 evokes myoblast 
apoptotic response via a novel signaling pathway involving S1P4 transactivation upstream of Rho-
kinase-2 activation. The FASEB Journal. 2013;27(11):4532-4546. 
136. Hu W-M, Li L, Jing B-Q, et al. Effect of S1P5 on proliferation and migration of human esophageal 
cancer cells. World Journal of Gastroenterology : WJG. 2010;16(15):1859-1866. 
 
138. Wang D, Zhao Z, Caperell-Grant A, et al. S1P differentially regulates migration of human ovarian 
cancer and human ovarian surface epithelial cells. Molecular cancer therapeutics. 2008;7(7):1993-
2002. 
139. Dziak R, Yang BM, Leung BW, et al. Effects of sphingosine-1-phosphate and lysophosphatidic 






140. Machida T, Matamura R, Iizuka K, Hirafuji M. Cellular function and signaling pathways of vascular 
smooth muscle cells modulated by sphingosine 1-phosphate. Journal of Pharmacological Sciences. 
2016;132(4):211-217. 
141. Bu S, Kapanadze B, Hsu T, Trojanowska M. Opposite Effects of Dihydrosphingosine 1-Phosphate 
and Sphingosine 1-Phosphate on Transforming Growth Factor-β/Smad Signaling Are Mediated 
through the PTEN/PPM1A-dependent Pathway. The Journal of Biological Chemistry. 
2008;283(28):19593-19602. 
142. Van Brocklyn JR, Lee M-J, Menzeleev R, et al. Dual Actions of Sphingosine-1-Phosphate: 
Extracellular through the G(i)-coupled Receptor Edg-1 and Intracellular to Regulate Proliferation and 
Survival. The Journal of Cell Biology. 1998;142(1):229-240. 
143. Ocwieja M, Meiser K, David OJ, et al. Effect of fingolimod (FTY720) on cerebral blood flow, platelet 
function and macular thickness in healthy volunteers. British Journal of Clinical Pharmacology. 
2014;78(6):1354-1365. 
144. Kimura T, Boehmler AM, Seitz G, et al. The sphingosine 1-phosphate receptor agonist FTY720 
supports CXCR4-dependent migration and bone marrow homing of human 
CD34&lt;sup&gt;+&lt;/sup&gt; progenitor cells. Blood. 2004;103(12):4478. 
145. Anada Y, Igarashi Y, Kihara A. The immunomodulator FTY720 is phosphorylated and released 
from platelets. European Journal of Pharmacology. 2007;568(1):106-111. 
146. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical 
Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature. Pharmacological Reviews. 
2010;62(4):579-587. 
147. Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K. Fingolimod for the 
treatment of relapsing multiple sclerosis. Expert Review of Neurotherapeutics. 2011;11(2):165-183. 
148. Im D-S, Heise CE, Ancellin N, et al. Characterization of a Novel Sphingosine 1-Phosphate 
Receptor, Edg-8. Journal of Biological Chemistry. 2000;275(19):14281-14286. 
149. Windh RT, Lee M-J, Hla T, An S, Barr AJ, Manning DR. Differential Coupling of the Sphingosine 
1-Phosphate Receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 Families of 
Heterotrimeric G Proteins. Journal of Biological Chemistry. 1999;274(39):27351-27358. 
150. Satsu H, Schaeffer M-T, Guerrero M, et al. A Sphingosine 1-phosphate receptor 2 selective 
allosteric agonist. Bioorganic & medicinal chemistry. 2013;21(17):5373-5382 
151. Jo E, Bhhatarai B, Repetto E, et al. Novel Selective Allosteric and Bitopic Ligands for the S1P(3) 
Receptor. ACS chemical biology. 2012;7(12):1975-1983. 
152. Dai L, Liu Y, Xie L, Wu X, Qiu L, Di W. Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P 
receptor axis is involved in ovarian cancer angiogenesis. Oncotarget. 2017;8(43):74947-74961. 
153. Wilkerson BA, Argraves KM. The role of sphingosine-1-phosphate in endothelial barrier function. 
Biochimica et biophysica acta. 2014;1841(10):1403-1412. 
154. Hsieh H-L, Wu C-B, Sun C-C, Liao C-H, Lau Y-T, Yang C-M. Sphingosine-1-phosphate induces 
COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells. 
Journal of Cellular Physiology. 2006;207(3):757-766. 
155. Hobson AD, Harris CM, van der Kam EL, et al. Discovery of A-971432, An Orally Bioavailable 
Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of 
Neurodegenerative Disorders. Journal of Medicinal Chemistry. 2015;58(23):9154-9170. 
156. Di Pardo A, Castaldo S, Amico E, et al. Stimulation of S1PR5 with A-971432, a selective agonist, 
preserves blood–brain barrier integrity and exerts therapeutic effect in an animal model of Huntington’s 
disease. Human Molecular Genetics. 2018;27(14):2490-2501. 
157 . Toman RE, Payne SG, Watterson KR, et al. Differential transactivation of sphingosine-1-






158. Gräler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M. The sphingosine 1-phosphate 
receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. Journal of Cellular 
Biochemistry. 2003;89(3):507-519. 
159. Donati C, Bruni P. Sphingosine 1-phosphate regulates cytoskeleton dynamics: Implications in its 
biological response. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2006;1758(12):2037-2048. 
160. Niedernberg A, Blaukat A, Schöneberg T, Kostenis E. Regulated and constitutive activation of 
specific signalling pathways by the human S1P(5) receptor. British Journal of Pharmacology. 
2003;138(3):481-493. 
161. Igarashi Y, Yatomi Y. Sphingosine 1-phosphate is a blood constituent released from activated 
platelets, possibly playing a variety of physiological and pathophysiological roles. Acta Biochim Pol. 
1998;45(2):299-309. 
162. Yatomi Y, Ruan F, Hakomori S, Igarashi Y. Sphingosine-1-phosphate: a platelet-activating 
sphingolipid released from agonist-stimulated human platelets. Blood. 1995;86(1):193. 
163 . Ye Y, Zhao Z, Xu H, et al. Activation of Sphingosine 1-Phosphate Receptor 1 Enhances 
Hippocampus Neurogenesis in a Rat Model of Traumatic Brain Injury: An Involvement of MEK/Erk 
Signaling Pathway. Neural Plasticity. 2016;2016:8072156. 
164. Greenspon J, Li R, Xiao L, et al. Sphingosine-1-Phosphate Protects Intestinal Epithelial Cells from 
Apoptosis Through the Akt Signaling Pathway. Digestive diseases and sciences. 2009;54(3):499-510. 
165. Kim J-H, Kim J-H, Song WK, Kim J-H, Chun J-S. Sphingosine 1-Phosphate Activates Erk-1/-2 by 
Transactivating Epidermal Growth Factor Receptor in Rat-2 Cells. IUBMB Life. 2008;50(2):119-124.  
166. Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S. Extracellular and Intracellular Actions of 
Sphingosine-1-Phosphate. Advances in experimental medicine and biology. 2010;688:141-155. 
167. Takeya H, Gabazza EC, Aoki S, Ueno H, Suzuki K. Synergistic effect of sphingosine 1-phosphate 
on thrombin-induced tissue factor expression in endothelial cells. Blood. 2003;102(5):1693. 
168 . Cheng J-C, Chang H-M, Liu P-P, Leung PCK. Sphingosine-1-phosphate induces COX-2 
expression and PGE2 production in human granulosa cells through a S1P1/3-mediated YAP signaling. 
Cellular Signalling. 2016;28(6):643-651. 
169. Ishii I, Friedman B, Ye X, et al. Selective Loss of Sphingosine 1-Phosphate Signaling with No 
Obvious Phenotypic Abnormality in Mice Lacking Its G Protein-coupled Receptor, LPB3/EDG-3. 
Journal of Biological Chemistry. 2001;276(36):33697-33704. 
170. Toyokuni T, Yatomi Y, Ruan F, Megidish T, , Hakomori S-i, Igarashi Y. N,N-Dimethylsphingosine 
Inhibition of Sphingosine Kinase and Sphingosine 1-Phosphate Activity in Human Platelets. 
Biochemistry. 1996;35(2):626-633. 
171. Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B, Spiegel S. N,N-Dimethylsphingosine Is a 
Potent Competitive Inhibitor of Sphingosine Kinase but Not of Protein Kinase C:  Modulation of Cellular 
Levels of Sphingosine 1-Phosphate and Ceramide. Biochemistry. 1998;37(37):12892-12898. 
172. Sundaramoorthy P, Gasparetto C, Kang Y. The combination of a sphingosine kinase 2 inhibitor 
(ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma 
cells without a t(11;14) translocation. Cancer Medicine. 2018;7(7):3257-3268. 
173. Britten CD, Garrett-Mayer E, Chin SH, et al. A Phase I Study of ABC294640, a First-in-Class 
Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 2017;23(16):4642-4650. 
174. Nitai C. Hait and Aparna Maiti, The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate 
in Inflammation and Cancer. Mediators of Inflammation, 2017; 4806541, 17  
175. Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 
and sorafenib in hepatocellular carcinoma xenografts. Cancer Biology & Therapy. 2011;11(5):524-534. 
176. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular 






177. Levkau B. HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic 
applications. Frontiers in Pharmacology. 2015;6:243. 
178. Asle-Rousta M, Oryan S, Ahmadiani A, Rahnema M. Activation of sphingosine 1-phosphate 
receptor-1 by SEW2871 improves cognitive function in Alzheimer's disease model rats. EXCLI Journal. 
2013;12:449-461. 
179. Sattler K, Gräler M, Keul P, et al. Defects of High-Density Lipoproteins in Coronary Artery Disease 
Caused by Low Sphingosine-1-Phosphate Content. Journal of the American College of Cardiology. 
2015;66(13):1470. 
180 . Alila Medical Mediam [online]https://www.shutterstock.com/image-illustration/blood-clotting-
process-117108244 [accessed 18/07/2018] 
181. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovascular 
Research. 2009;82(2):193-200. 
182. Bae J-S, Yang L, Rezaie AR. Factor X/Xa Elicits Protective Signaling Responses in Endothelial 
Cells Directly via PAR-2 and Indirectly via Endothelial Protein C Receptor-dependent Recruitment of 
PAR-1. Journal of Biological Chemistry. 2010;285(45):34803-34812. 
183. di Villa Bianca Rd, Emmanuele, Sorrentino R, et al. Sphingosine 1-Phosphate Induces Endothelial 
Nitric-Oxide Synthase Activation through Phosphorylation in Human Corpus Cavernosum. Journal of 
Pharmacology and Experimental Therapeutics. 2006;316(2):70 
184. Jin Z-Q, Karliner JS. Low dose N, N-dimethylsphingosine is cardioprotective and activates 
cytosolic sphingosine kinase by a PKCε dependent mechanism. Cardiovascular Research. 
2006;71(4):725-734. 
185. Brinkmann V, Cyster JG, Hla T. FTY720: Sphingosine 1-Phosphate Receptor-1 in the Control of 
Lymphocyte Egress and Endothelial Barrier Function. American Journal of Transplantation. 
2004;4(7):1019-1025. 
186. Rivera-Nieves J. Strategies that Target Leukocyte Traffic in IBD: Recent Developments. Current 
opinion in gastroenterology. 2015;31(6):441-448. 
187 . Park S-J, Im D-S. Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery. 
Biomolecules & Therapeutics. 2017;25(1):80-90. 
188. Kim H-J, Jung C-G, Dukala D, et al. Fingolimod and related compounds in a spontaneous 
autoimmune polyneuropathy. Journal of neuroimmunology. 2009;214(1-2):93-100.  
189. Zhao Y, Shi D, Cao K, et al. Fingolimod targets cerebral endothelial activation to block leukocyte 
recruitment in the central nervous system. Journal of Leukocyte Biology. 2018;103:107–118. 
